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The transmembrane glycoprotein MUC1 is aberrantly expressed in the majority
of pancreatic ductal adenocarcinoma cases and promotes tumor progression by
engaging in morphogenetic signaling through its cytoplasmic tail. Furthermore, MUC1
can translocate to the nucleus and function as a transcriptional co-regulator in
conjunction with transcriptional complexes containing activator protein-1 (AP-1) and p53.
The specificity of these interactions are thought to rely on specific patterning of posttranslational modifications within the cytoplasmic tail of MUC1.
Within this dissertation, we examined how MUC1 influences the formation and
activity of these transcription factors and the resulting impact on tumor progression and
metastasis. In our first set of studies, we evaluated the global pattern of posttranslational modifications present within MUC1. While previous studies have shown
phosphorylation of specific residues, we found that MUC1 exists in a
hyperphosphorylated state containing potentially more than 10 phosphorylated residues.
Furthermore, malignant tumors exhibit a higher degree of phosphorylation and changes
in the environment also drive changes in this patterning. This is also true of several
MUC1 splice variants, suggesting that MUC1 can readily integrate numerous signaling
pathways to initiate the appropriate signaling compartment.
We further evaluated how MUC1 expression regulates the function of AP-1 and
found that MUC1 promoted the formation of AP-1 dimers consisting of c-Jun and FRA-1.
We further demonstrated that FRA-1 is a novel driver of pancreatic tumor migration,
invasion, and overall progression both in conjunction, and independent of MUC1
expression. In vivo studies show increased expression of FRA-1 in pancreatic cancer
and increased expression of FRA-1 target genes involved in epithelial-to-mesenchymal
transition suggesting FRA-1 may be a potential therapeutic target in pancreatic cancer.
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We explored this possibility utilizing inhibitors of bromodomain and extraterminal
domain containing proteins, which had shown inhibitory effects on expression of FRA-1.
We found we were unable to reproduce these effects, however, combining FRA-1
knockdown with BET inhibition resulted in additive effects in decreasing cellular growth.
These effects are seemingly due to diminished expression of pro-growth and survival
genes. Future studies targeting FRA-1 may identify better therapeutic partners.
Lastly, we examined how the mutational status of p53 influenced its interaction
with MUC1. As mutant p53 has been shown to exhibit gain-of-function effects in cancer,
we sought to evaluate whether different mutants would preferentially interact with MUC1
and any potential transcriptional changes that result. We found that MUC1 preferentially
interacted with the hotspot mutant R273H, as compared to R175H and wildtype p53 in a
dox-inducible model.
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CHAPTER I: INTRODUCTION
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1. Pancreatic Cancer
1.1 Diagnosis, Prognosis and Treatment
Pancreatic cancer is currently the fourth-leading cause of cancer related deaths
within the United States [1, 2]. This is projected to rise to the second-leading cause of
cancer-related death by 2020 [3]. Despite extensive research focused on therapeutic
treatment of cancer, the prognosis for patients diagnosed with pancreatic cancer
remains poor, even as survival for other cancers have shown marked improvements.
Furthermore, the majority of pancreatic cancer cases are the aggressive pancreatic
ductal adenocarcinoma (PDAC), as opposed to the less malignant neuroendocrine
tumors[4]. The current five-year survival rate for pancreatic cancer is approximately 6%
and has remained largely unchanged for decades[2]. Surgical resection of the pancreas
is the best option for patient survival, and patients that have undergone the Whipple
procedure have a five-year survival rate near 20%[2, 5, 6]. However, due to the location
of the tumor, non-specific symptoms at presentation, and propensity for distal
metastases at diagnosis, only a fraction of patients are eligible for the procedure.
Studies for early biomarkers of pancreatic cancer are currently ongoing, however, have
not yet made a significant impact on the diagnosis of PDAC.
Over the past two decades the standard treatment of pancreatic cancer has
largely consisted of the deoxycytidine analogue gemcitabine either alone, or in
conjunction with other chemotherapeutic drugs, most recently Abraxane™ [7, 8]. The
multidrug combination FOLFIRINOX has shown potential for extension of patient
survival, however, the regimen is associated with significant toxicity [7, 9]. Ultimately
none of the current standard therapies for pancreatic cancer provide curative benefit to
patients, as the disease often resists treatment, either through intrinsic or adaptive
mechanisms [10]. The molecular mechanisms involved in the formation and progression
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of pancreatic cancer must be elucidated to identify novel therapeutic targets and improve
the outcome of patients.

1.2 Genetics and Development
PDAC develops through the accumulation of genetic alterations that confer a
selective advantage upon the cells. While the majority of pancreatic cancer cases are
ductal adenocarcinoma, the precise cell of origin remains debated. As the ductal cells
represent a minor fraction of the pancreas, it is hypothesized that acinar-to-ductal
metaplasia (ADM) plays a major role in the development of pancreatic cancer [11]. As
mutations accumulate, the normal epithelia of the pancreas undergo transition to
pancreatic intraepithelial neoplasias (PanINs), eventually developing into invasive
adenocarcinoma [12]. This transition is well defined, as cells progress from PanIN-1
through PanIN-3 with increasing dysplasia before ultimately becoming invasive disease
(Figure 1.1). The histology of pancreatic cancer is characterized by robust stromal
involvement and desmoplasia with the actual cancer cells representing a minor fraction
of the tumor (Figure 1.2). This stromal reaction has significant impact on the treatment
of PDAC as it creates a cellular, molecular, and physical barrier for drug delivery and
entry of effector lymphocytes and other immune cell types.
There are four major genetic alterations that commonly occur within pancreatic
cancer [13]. More than 90% of pancreatic cancers exhibit activating mutations within the
Kras oncogene and 50-75% of tumors exhibit alterations in the tumor suppressor p53
[14]. These two alterations are sufficient to induce spontaneous pancreatic tumor
development when engineered for pancreas cell specific expression in mice and provide
the basis for the KPC mouse model of spontaneous pancreatic cancer [15]. In addition
to these two drivers, loss of the CDKN2A locus and SMAD4 are also extremely common
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[13]. Beyond the four common mutations, pancreatic cancer harbors patient specific
mutations within a number of alternative pathways promoting oncogenic signaling
through several distinct networks. As a result, pancreatic cancer represents a diverse
malignancy that is proposed to consist of distinct molecular subtypes [16-18]. Most
recently, it has been proposed that PDAC consists of four distinct subtypes based on
combined genomic, epigenomic, and transcriptomic analyses, however, the conclusions
from these studies remain controversial as tumors are often complicated by
contamination by stromal cells [18]. Each of these subtypes appears to utilize different
signaling pathways for growth and progression. Interestingly, expression of different
mucin glycoproteins correlates with different subtypes of pancreatic cancer.
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Figure 1.1: Development of Pancreatic Ductal Adenocarcinoma
The progression of events involved in the development of pancreatic ductal
adenocarcinoma is well defined[12]. During development, lesions progress through a
number of well-characterized stages (PanIN-1 through 3) before finally progressing to
invasive carcinoma. Among the earliest events is the mutation of Kras, typically at
hotspot residues 12 and 13. Other well-characterized events included loss of tumor
suppressors such as p16, p53, and SMAD4.

Figure 1.1
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Figure 1.2: Histology of Pancreatic Ductal Adenocarcinoma
Images representing either normal pancreas (A) or pancreatic ductal adenocarcinoma
(B) are presented. Slides were counterstained with hematoxylin and scanned at 40X
magnification using the Ventana Coreo slide scanner in the UNMC Tissue Sciences
Core. Normal pancreas consists of both an exocrine and endocrine compartment. The
exocrine function primarily consists of acinar cells, with a minor fraction of ductal cells,
and cells within the Islet of Langerhans control the endocrine function. In comparison,
pancreatic ductal adenocarcinoma exhibits an intense stromal reaction and in many
tumors the proportion of stroma exceeds that of the tumor cells.

Figure 1.2

Normal Pancreas

Pancreatic Ductal Adenocarcinoma
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2. Mucins
2.1. Structure and Function
Mucins comprise a large family of glycoproteins expressed by a variety epithelia;
including the respiratory, gastrointestinal, and reproductive tracts [19]. These high
molecular weight glycoproteins are classified as either secretory mucins, which are
secreted into the extracellular space, or membrane bound mucins that contain a
transmembrane domain and are inserted into the apical surface of epithelial cells [19,
20]. Together these mucins make up a significant proportion of the proteins found in the
mucosal layers that coat the epithelial surface at the air to cell interface [20-23]. The
secretory family of mucins includes MUC2, MUC5AC, MUC5B, MUC6, and MUC7,
whereas, MUC1, MUC3A, MUC3B, MUC4, MUC12, MUC13, MUC15, MUC16, MUC17,
and MUC20 are all membrane bound [20]. Under normal physiological conditions,
mucins play an essential role in lubrication, chemical sensing, and organization of the
local microenvironment surrounding the cells [19]. Mucins also form a protective barrier
to pathogens and are postulated to act as sensors of the surrounding environmental
conditions [24-26]. Transmembrane mucins can propagate extracellular signals into the
cells through phosphorylation of specific residues in the cytoplasmic tail, allowing cells to
adapt to the surrounding environment [26].
A defining structural characteristic of mucin proteins is the presence of a tandem
repeat domain or mucin domain [20]. The amino acid sequence and number of these
repeats varies from mucin to mucin and are rich in serine, threonine, and proline
residues resulting in the presence of many potential sites of O-linked glycosylation [27,
28]. The presence of O-glycosylation is critical for mucin function, as these
oligosaccharides are involved in ligand-receptor interactions and mediate the gel-forming
properties critical for organization of the extracellular environment [29, 30]. As the
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number of these repeats is highly variable, individual mucins can contain a wide array of
potential glycosylation patterns [20] (Figure 1.3).
The process by which mucin type O-linked glycosylation occurs is well
characterized [31-34] (Figure 1.4). The initiating step involves the addition of N-acetylGalactosamine (GalNAc) to serine or threonine residues present in the mucin backbone
to form the Tn-epitope and is catalyzed by a large family of enzymes called GalNActransferases (GalNAc-Ts) [31, 35]. These structures can then be further extended to
form Core 1, 2, 3, or 4 structures based on the identity and linkage of the carbohydrate
moiety [36]. Core 1 structures are formed by addition of Galactose (Gal) in a β1-3
linkage to GalNAc. In contrast to the diversity of GalNAc-Ts, a singular enzyme, Core 1
Gal-transferase, catalyzes this addition [37]. Core 1 structures can then be extended or
Core 2 structures can be generated by addition of GlcNAc in a β1-6 linkage to the
existing GalNAc of the Core 1 structure by C2GnTs [38-40]. As an alternative to Core 1,
Core 3 structures can be generated through addition of GlcNAc in a β1-3 linkage to the
Tn epitope [41]. Like Core 1 structures, Core 3 structures may be extended or act as the
scaffold for Core 4 structure generation through addition of another GlcNAc in a β1-6
linkage [40]. While other core structures do exist, Core 1, 2, 3, and 4 structures
comprise the primary glycan structures observed with the human body.

2.2 Deregulation of mucin expression and O-glycosylation in Cancer
Deregulated expression of mucins is observed in many malignancies, particularly
within adenocarcinomas (Table 1.1). Elevated expression of MUC1 is common in
pancreatic, breast, colon, lung, and prostate cancer [42-45]. Expression of MUC1
appears to be a major factor in the progression of pancreatic cancer, as knockout of
MUC1 results in significantly prolonged survival in the KPC mouse model of pancreatic
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cancer (Figure 1.5). This effect is presumably through the oncogenic signaling capacity
of the MUC1 cytoplasmic tail. Similarly, knockout of MUC1 expression in a mouse
model of mammary tumors also delayed tumor progression [46]. MUC4 expression is
increased in colon adenocarcinoma samples and is a proposed marker of aggressive
pancreatic cancer [42, 47]. Elevation of the MUC16 marker (CA125) is well studied in
ovarian cancer, however, more recently expression of MUC16 has been implicated as a
significant factor in the progression of pancreatic cancer[48-51].
Additionally, many tumors exhibit increased expression of truncated or aberrant
O-glycans. These alterations in tumor glycobiology primarily occur through 2
mechanisms; Neo-synthesis or incomplete synthesis [52]. In particular, the expression
of Core 1 based structures, such as T, Tn, or sialyl-Tn(STn), are observed in a majority
human carcinomas, whereas in healthy tissues, these structures are typically absent [42,
53, 54]. Increased expression of other glycoepitopes, such as sialyl-Lewisx/a, are also
commonly observed [55]. In contrast, decreased expression of Core 3 and 4 structures
are observed in gastric and colorectal cancers [56, 57]. In many instances, expression
of these structures is driven by alterations in the expression of enzymes involved in the
glycosylation process. For example, the extension of Core 1 structures relies on a single
enzyme, C1GalT1. This enzyme requires a specific chaperone, COSMC, for proper
folding and functional activity [58-60]. Cells lacking expression of COSMC have been
shown to express increased levels of Tn and STn epitopes [61, 62]. Furthermore, a
significant percentage of cancers exhibit hypermethylation of the COSMC gene,
resulting in decreased expression of C1GalT1 and increased formation of Tn and STn
epitopes [63]. Deregulation of other enzymes involved in O-linked glycosylation has
been observed in a variety of cancers [55, 64-68].
Expression of these aberrant glycoforms is often used as a diagnostic or
prognostic marker of tumor progression. CA19-9 detects the presence of sialyl lewisa on
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mucin core proteins[69, 70]. Other markers include DuPan-2, Span-1, CA50, CA242,
CA195, CAM43, and SSEA[70-72]. All of these markers are mucin type
oligosaccharides. While the levels of these markers are commonly monitored
throughout tumor progression the sensitivity and specificity of these assays as
diagnostic tools is relatively poor. As such, use of these assays has not proven useful
for early diagnosis of pancreatic cancer.
Phenotypically, expression of aberrant O-glycans has been correlated with
increased aggressiveness and metastatic behavior in a variety of cancers [53, 55, 63].
These effects are hypothesized to be the result of altered interactions between tumor
cells and binding partners in the extracellular environment, such as selectins and
integrins [55]. However, these alterations may result in perturbations to the signaling of
mucin cytoplasmic tails leading to potentiation of oncogenic signals. Re-expression of
enzymes involved in the extension of the carbohydrate chain, such as Core 3 synthase,
results in a decrease in these aggressive properties in pancreatic cancer cells by
influencing these interactions suggesting that targeting the glycosylation process may be
a viable strategy in cancer [73].

2.3 MUC1: Signaling Through the Cytoplasmic Tail
MUC1 is the best-characterized transmembrane mucin for its signaling role within
tumorigenesis; however, both MUC4 and MUC16 have also been shown to signal
through their cytoplasmic tails [74, 75]. MUC1 is a type I transmembrane protein that
exists as a heterodimer at the apical cell surface. The formation of the dimer is through
an autoproteolytic cleavage event that occurs during translation of MUC1 at the SEA
(sea urchin sperm protein, enterokinase, agrin) domain [19, 20, 76]. The resulting two
subunits then associate in a strong, non-covalent interaction. The protein undergoes
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extensive glycosylation, both O-linked and N-linked, before insertion into the plasma
membrane [19, 20](Figure 1.6). The N-terminus of MUC1 consists of a heavily Oglycosylated extracellular portion that extends from the cell surface and plays a role in
organization of the glycocalyx [20]. The C-terminus of MUC1 (MUC1.CT) consists of a
short extracellular domain, a transmembrane domain, and a 72 amino acid cytoplasmic
tail.
In response to perturbations of the extracellular environment, binding of ligand
molecules, or interaction with receptor tyrosine kinases (RTKs), MUC1 can become
phosphorylated at specific residues within the cytoplasmic tail [26, 77-79]. Under normal
physiological conditions, MUC1 is spatially separated from RTKs that are expressed on
the basal surface. Loss of polarity, either through mechanical injury of the epithelia or as
a result of cellular transformation, allows MUC1 to interact with these partners and drive
downstream signaling (Figure 1.7)[26]. As the cytoplasmic tail of MUC1 contains 22
potential sites of phosphorylation, it is possible to integrate a wide range of signals
through specific phosphorylation patterns. This combinatorial pattern of phosphorylation
is likely critical for the specificity of interactions of the cytoplasmic tail with a host of
effectors [77, 80-82] (Figure 1.8).
As a result of all these potential interaction partners, the propagation of signals
through the cytoplasmic tail is extremely complex (Figure 1.9). Interaction of MUC1 with
receptor tyrosine kinases can result in the activation of a number of downstream
cascades. Phosphorylation of the MUC1 cytoplasmic tail has been shown to increase
the interaction of MUC1 with Grb2 to drive downstream activation of ERK [81, 83].
MUC1 also promotes signaling through the PI3K/Akt signaling pathway to drive antiapoptotic signaling [84, 85]. MUC1 also interacts with all four members of the ErbB
family of receptor tyrosine kinases [86]. Other studies have shown that MUC1 is
capable of initiating signaling through JNK to drive migration and invasion in
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hepatocellular carcinoma[87, 88]. Induction of these signaling cascades results in
eventual activation of transcriptional effectors, such as NF-κB and C/EBP, to alter the
expression of genes critical in tumor progression and survival[81, 85, 89].
These interactions can also result in alterations to localization of signaling
complexes. The interaction of MUC1 with the EGFR receptor results in not only
phosphorylation of MUC1, but also in nuclear localization of EGFR [79]. How MUC1
translocates to the nucleus remains unknown, however, it may depend on endosomal
internalization, similar to the mechanism of nuclear localization of ErbB2 [90]. Supporting
this idea is the evidence that both MUC1 and EGFR can associate with CIN85, which
regulates internalization of EGFR [91, 92]. Furthermore, the presence of specific
tyrosine residues in the cytoplasmic tail is critical for clathrin-mediated endocytosis of
MUC1, suggesting that phosphorylation of MUC1 may be a critical determinant in the
localization of signaling complexes [93].
MUC1 expression also has significant impact on the surrounding tumor
microenvironment through interactions with the surrounding stroma and tumor
associated cells. Expression of select carbohydrate epitopes on MUC1 has been shown
to promote the invasion of pancreatic cancer cells into the surrounding vascular [94]. As
a result, MUC1 regulates the adhesive and anti-adhesive balance within the tumor.
MUC1 has also been shown to play an immunomodulatory role through interactions with
specific immune effector cells [95-97]. While these interactions are thought to be
primarily immunosuppressive, the presence of anti-MUC1 autoantibodies within tumor
patients suggests that MUC1 may be a viable target for immunotherapies [98, 99].
Specific studies have also demonstrated the capacity of MUC1.CT to interact
with the transcription factors p53 and c-Jun [77, 80, 100]. The interaction of MUC1.CT
with transcription factors is proposed to result in the translocation of MUC1 to the
nucleus where it acts as a transcriptional co-regulator. The interaction of MUC1 and p53
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has been shown to promote survival based signaling by promoting expression of p21,
while inhibiting expression of the pro-apoptotic protein Bax [80]. This suggests that
MUC1 may promote tumor cell survival by altering the normal function of p53 or by
promoting gain-of-function effects with mutant p53. While MUC1 has no DNA binding
capacity, it is found in complex with p53 at these promoter elements suggesting that
MUC1 can modulate the formation of transcriptional complexes. Additional studies
have shown that this interaction requires phosphorylation of specific motifs within the
cytoplasmic tail [77]. These studies have also demonstrated that these complexes
appear to impact the expression of connective tissue growth factor (CTGF) and matrix
metalloprotease 1 (MMP1) through the binding of upstream promoter elements [77, 100].
This binding is accompanied by the apparent loss of the proto-oncogene, c-Jun, from the
same promoter element. How the mutational status of p53 influences the interaction with
MUC1.CT and the resulting impact on gene expression is unknown.
MUC1 has also been shown to associate with β-catenin through a serine rich
motif present in the cytoplasmic tail [101, 102]. This motif is similar to the serine rich
motif of APC that allows for interaction with β-catenin. Like the association with p53, this
interaction has shown to promote translocation of MUC1 to the nucleus and alter the
regulation of Wnt target genes [103]. This interaction is modulated by phosphorylation of
specific residues in the cytoplasmic tail. Phosphorylation of a serine residue near the
serine rich motif by GSK3β decreases the affinity of this interaction, whereas
phosphorylation of tyrosine residues by c-Src appears to increase the affinity of MUC1
for β-catenin [104, 105]. These interactions may also influence the balance of adhesive
properties by changing the localization of β-catenin from junctional complexes.
Translocation of MUC1 to the mitochondrial membrane has also been observed
in select circumstances [106]. In these studies, MUC1 was shown to inhibit pore
formation by interfering with Bax oligomerization. This binding requires the CQC motif
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present within the cytoplasmic tail of MUC1. This association results in inhibition of
cytochrome C release and blocking of the apoptotic pathway. The translocation of
MUC1 to the mitochondria appears to rely on the association with the molecular
chaperone Hsp90 [107]. Interestingly, expression of MUC1 has also been shown to
promote FasL induced apoptosis suggesting MUC1 may balance several apoptotic
pathways [108]. Supporting this idea is the evidence that MUC1 expression is often
induced in response to cellular stressors, such as presence of reactive oxygen species
(ROS) [109].
As a result of all these interactions, MUC1 acts as a signaling hub for an
extremely complex network of pathways. How MUC1 integrates all these pathways to
initiate the correct downstream effect remains unknown. Furthermore, how MUC1
exerts its transcriptional co-regulatory role is still not fully understood. MUC1 appears to
alter the formation of transcriptional machinery, however, whether these complexes are
altered through direct association with MUC1 or through indirect alterations to upstream
signaling cascades is unknown. Therefore further study of the molecular mechanisms
involved in mucin signaling is needed.
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Table 1.1: Deregulation of Mucin Expression in Cancer
Table list mucins for which expression is altered in different cancers. References are
included for each cancer presented.
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Table 1.1

Deregulation of Mucin expression in Cancer
Mucin
MUC1, MUC4, MUC5AC,
MUC6, MUC16
MUC1, MUC2, MUC3,
MUC4, MUC5AC, MUC5B,
MUC6
MUC1, MUC2, MUC4,
MUC5AC, MUC5B, MUC6,
MUC17
MUC1, MUC2, MUC4,
MUC5AC, MUC6

Cancer
Pancreatic Ductal
Adenocarcinoma

Breast Cancer
Colon Cancer
Lung Cancer

MUC1, MUC4, MUC16

Ovarian Cancer

MUC1, MUC2, MUC4

Prostate Cancer

MUC1, MUC2, MUC3,
MUC4, MUC5AC, MUC5B,
MUC6, MUC13

Gastric Cancer

Reference
Remmers, et al[53]
Hinoda, et al[110]
Huang, et al[111]
Haridas, et al[51]
Higashi, et al[50]
Ghosh, et al[112]
Rakha, et al[113]
Mukhopadhyay, et al[114]
Terada, et al[115]
Krishn, et al[42]
Awaya, et al[44]
Kwon, et al[116]
Yin, et al[117]
Chauhan, et al[118]
Singh, et al[45]
Osunkoya, et al[119]
Ho, et al[120]
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Figure 1.3: Structural Organization of MUC1, MUC4, and MUC16
Schematic representing the domain organization of the mucins: MUC1, MUC4, and
MUC16. Structures are not drawn to scale. These mucins contain cleavage sites
(highlighted by dashed line) and exist at the cell surface as a dimer. In addition to the
common mucin repeat domain, each mucin contains regions of unique sequences
conferring specific functions. The sequence of the cytoplasmic tails is presented with
confirmed sites of phosphorylation (*) indicated.
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Figure 1.4: Mucin Type O-Glycosylation
Schematic representing the addition of carbohydrates involved in mucin type Oglycosylation. Initiation involves addition of GalNAc to serine or threonine residues
present in the mucin backbone to form the Tn epitope. These structures can be further
extended into Core 1,2,3, or 4 structures depending on the identity of the carbohydrate.
In cancer, the formation of truncated glycans (highlighted in red box) is common due to
disruption of normal enzymatic function.
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Figure 1.5: Loss of MUC1 Extends KPC Survival
MUC1 wildtype and KO KPC mice were generated by crossing the standard MUC1 KO
mouse into the KPC mouse model of pancreatic cancer. Survival was tracked over time
and a Kaplan-Meier plot showing survival of KPC mice that are either wildtype for MUC1
expression or have MUC1 knocked-out was generated based upon the survival data.
Death from cancer was confirmed by necropsy. Statistics were performed using 2-way
ANOVA.
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Figure 1.6: Processing of MUC1
Following translation, MUC1 undergoes an autoproteolytic cleavage at its SEA domain.
These two subunits are associated through a strong, non-covalent interaction. MUC1
then undergoes further processing in the Golgi with the attachment of carbohydrates in
an O- (Serine/Threonine) and N-linked (Asparagine) fashion. MUC1 is then inserted into
the plasma membrane and displayed at the cell surface.
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Figure 1.7: Model of MUC1 Activation in Response to Loss of Polarity
Figured based upon hypotheses presented in Singh, et al[26]. Under normal
physiological conditions MUC1 and receptor tyrosine kinases (RTKs) are spatially
separated. However, with loss of normal junctional complexes through mechanical
injury or loss of polarity due to malignant transformation, MUC1 and RTKs can associate
to drive downstream signaling cascades that determine cellular fate.
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Figure 1.8: Known Interaction Partners of the MUC1 Cytoplasmic Tail
A schematic of the MUC1 cytoplasmic tail and known regions involved in the association
with signaling partners. Phosphorylation sites with known kinases are highlighted in red
text. Additional interaction partners are also shown below. These additional partners do
not have known sites of interaction.
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Figure 1.9: Model of MUC1 Signaling in Cancer
MUC1 has been shown to initiate pro-oncogenic effects through a number of distinct
mechanisms. 1) MUC1 can interact with RTKs (or other kinases) resulting in
phosphorylation of the cytoplasmic tail. 2) MUC1 can as a chemical sensor of the
surrounding environment and sequester various factors from the extracellular
environment. 3) MUC1 can interact with and organize the surrounding
microenvironment. 4) MUC1 propagates signals through a number of downstream
effector pathways. 5) MUC1 can regulate the compartment of signaling in association
with other factors. 6) MUC1 can translocate to the nucleus in association with
transcription factors to alter gene expression. 7) Translocation of MUC1 to the
mitochondrial membrane to inhibit the apoptotic response
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3. AP-1
3.1 Structure and Function
Activator Protein-1 (AP-1) is a dimeric transcription factor canonically consisting
of either a homodimer of Jun proteins or a heterodimer of Jun and Fos proteins [121].
The initial discovery and characterization of this factor demonstrated significant affinity
for a common cis-element in the promoters of genes regulated by addition of phorbol
esters, such as 12-O-tetradecanoyl-phorbol-13-acetate (TPA) [122, 123]. These
promoter elements were termed TPA-response elements (TREs) and are among the
best-defined sites of AP-1 binding [123]. The consensus sequence for the TRE is
TGAC/GTCA. Interestingly, the individual components of AP-1 were discovered as viral
oncogenes prior to the identification of the cellular homologs. V-Jun was discovered in
the viral genome of avian sarcoma virus, whereas v-Fos was discovered within the
genome of FBJ-murine osteosarcoma virus [124, 125]. Subsequent studies discovered
the cellular homologs, c-Jun and c-Fos, which constitute mammalian AP-1.
Within humans there are 3 distinct JUN family members (c-Jun, JunB, and JunD)
and 4 FOS family members (c-Fos, FosB, FRA-1, and FRA-2) [121, 126]. These
proteins are part of a larger class of proteins called Bzip proteins that contain a basic
region that facilitates the binding of DNA, and a leucine zipper for dimerization. A high
degree of similarity exists across family members, particularly within the Bzip domain
suggesting potential functional redundancy to a degree (Figure 1.10). Typically,
functional dimerization of AP-1 proteins is dependent on phosphorylation of residues that
stabilize the proteins. Phosphorylation of the delta domain in c-Jun is critical for
regulation of its stability and is absent in the viral homolog v-Jun [127]. Phosphorylation
of serines 63 and 73 within this domain, results in stabilization of the protein, and
functional activity [128, 129]. However, it also creates binding sites for regulatory
proteins that turn off the transcriptional signals by degrading c-Jun [130]. Similarly, the
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stability of c-Fos and FRA-1 is regulated by the presence of a C-terminal degradation
sequence [131, 132]. Like v-Jun, v-Fos lacks this domain and as a result is significantly
more stable than its normal cellular counterpart [133]. Similarly, truncated ΔFosB that
lacks the C-terminal degradation sequence also exhibits prolonged stability
demonstrating that these sequences are critical for the regulation of Fos family proteins
[134]. Phosphorylation of residues near the basic region has also been shown to
regulate DNA binding of AP-1 proteins, presumably by altering the net positive charge
required to associate with DNA [135].

3.2 Roles of Jun and Fos in Normal Development
The role of Jun and Fos proteins in normal developmental processes has been
well studied through the generation of specific knockout mice (Table 1.2). Both
knockouts of c-Jun and JunB are embryonic lethal at E12.5 and E10 respectively [136,
137]. Knockout of c-Jun results in significant abnormalities in the heart and liver [136,
138]. Defects in hepatocyte proliferation are maintained throughout adulthood, as
perinatal liver specific deletion of c-Jun results in defects in liver regeneration following
partial hepatectomy [139]. JunB knock-in can rescue the embryonic lethal phenotype of
c-Jun knockout, however, mice still only survive a few days beyond birth [140].
Interestingly, these mice show normal induction of Jun/Fos target genes, however, are
unable to induce genes regulated by Jun/ATF dimers, suggesting only partial
redundancy between these proteins. Indeed, in other studies, c-Jun and JunB were
shown to exert antagonistic effects [141, 142]. Overexpression of either c-Jun or JunB
in transgenic mice shows no overt phenotype [143, 144]. Unlike c-Jun and JunB, JunD
knockouts are viable; however, males exhibited impaired growth, hormone imbalances,
and defects in reproduction due to faulty spermatogenesis [145].
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FRA-1 is the only Fos protein whose knockout results in embryonic lethality. This
occurs at approximately E9.5 [146]. The embryonic lethality of FRA-1 knockout is due to
defects in placental development [147, 148]. Interestingly, these defects can be
completely rescued by providing wild-type extra-embryonic tissues during development.
These rescued mice display no overt phenotype suggesting that beyond placental
development FRA-1 expression may be dispensable for normal developmental
processes [146]. Interestingly, expression of JunB in place of FRA-1 can also partially
rescue development, suggesting that JunB and FRA-1 may have similar functions in
early development [146]. The similar phenotypes between the knockouts of these mice
further support this. Overexpression of FRA-1 results in accelerated osteoblast
differentiation and increased bone formation in mice [149].
Knockout of c-Fos results in viable mice, however, these mice lack osteoclasts
[150, 151]. These mice also exhibit secondary alterations to the hematopoietic system,
however; further studies have shown that c-Fos is dispensable for function of peripheral
T-cells [152, 153]. Knock-in of FRA-1 in place of c-Fos is able to restore normal bone
development demonstrating substantial redundancy between these proteins in normal
development [154]. By comparison, overexpression of c-Fos further exacerbates the
impact on bone development and promotes formation of osteosarcomas[155].
FosB null mice also develop normally, however, some studies have
demonstrated that loss of FosB expression results in nurturing defects [156, 157].
Overexpression of FosB results in no discernable phenotype [144]. Unlike the other Fos
proteins, FosB also exists as the variant ΔFosB. Overexpression of this splice variant
results in disruption of normal cellular differentiation particularly within osteoblasts and Tcells [158, 159]. FRA-2 knockout results in disruptions to normal cartilaginous
development and these mice die shortly after birth [160]. Overexpression of FRA-2
results in ocular abnormalities [161].
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These knockout studies demonstrate the diverse range of function associated
with AP-1. Despite the prediction that these proteins must functionally dimerize to exert
functional effects, only JunB and FRA-1 knockouts exhibit similar phenotypes. Knock-in
studies have demonstrated that these proteins do retain functional equivalency under
some circumstances, however, in many instances these knock-ins only rescue part of
the knockout phenotype. This suggests that these proteins also play unique roles within
development. For example, in fibroblasts c-Jun is a positive regulator of cellular
proliferation, whereas both JunB and JunD are negative regulators [138, 162-165].
These effects also appear to be context dependent as expression of c-Jun is critical for
apoptosis in neuronal cells [166, 167].

3.3 AP-1 in Tumorigenesis
The formation of cancer involves deregulation of numerous cellular pathways
[168]. These include disruptions to normal cellular proliferation, evasion of the immune
system, resistance to cell death, the induction of angiogenesis, and the activation of
pathways involved in invasion and metastasis. Interestingly, AP-1 has been shown to
play a role in virtually every pathway associated with tumorigenesis [162, 164, 169172](Figure 1.11).
The oncogenic potential of both c-Jun and c-Fos is well known as the cellular
homologs of the viral oncogenes v-Jun and v-Fos [125, 173]. The oncogenic potential of
c-Fos is dependent on the ability of c-Fos to functionally dimerize, as well as the
maintenance of several structural motifs within the N and C-terminus [174-177].
Transformation of mammalian cells by c-Jun requires co-expression of oncogenic
drivers, such as Ras, as well as the transactivation domain and the phospho-acceptor
residues serine 63 and 73 [128, 178, 179]. Expression of c-Jun also results in decreased
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expression of both p53 and p21 suggesting that c-Jun may interfere with normal tumor
suppressor function [162]. Similar to c-Fos, FosB has also shown transformative
potential in fibroblasts [180]. This potential also requires the presence of conserved
motifs, particularly within the C-terminus [180-182].
The transformative potential of the other fos proteins (FRA-1 and FRA-2) are
both weak by comparison. Overexpression of FRA-1 in fibroblasts does not result in
significant morphological changes, but does promote anchorage-independent growth
and tumor formation in nude mice [183, 184]. Despite the relatively weak transformation
potential, expression of FRA-1 has also been shown to correlate with poor prognosis in
breast cancer and drive an invasive phenotype [185-188]. Expression of FRA-1 in
colorectal cancer also results in expression of genes involved in epithelial-tomesenchymal transition (EMT) [170, 189]. FRA-2 is capable of transformation in
chicken fibroblasts, but not rat fibroblasts [190, 191]. Interestingly, both JunB and JunD
lack any known transforming activity [143, 192]. Furthermore, several studies have
indicated that these proteins may actually act as tumor suppressors [163, 165].

3.4 Dimer Specific Functions of AP-1
While studies of human tumors have shown that expression of Jun and Fos
proteins is altered in a wide range of cancers, the role that AP-1 plays in many of these
tumors remains poorly understood; particularly with regard to the specific dimers working
within these cells [170, 186, 193-195]. Due to the diverse phenotypes associated with
different Jun and Fos proteins, it is likely that the composition of AP-1 is a critical
determinant of the function. Based on the dimerization properties of Jun and Fos
proteins, there are 18 potential dimer combinations; ignoring non-canonical dimers such
as Jun:ATF and FRA1:Smad dimers (Figure 1.12). Several studies have demonstrated
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that dimer composition can influence the DNA binding properties of AP-1 [196-199].
Studies using tether dimers of known composition have demonstrated that unique
dimers regulate specific cellular effects, such as c-Jun:FRA-2 dimers inhibiting G0 arrest
in 3T3 cells [198]. Jun and ATF dimers have been shown to specifically regulated
growth factor independence [196]. FRA-1:Smad dimers have also shown to regulate
invasive properties in response to TGFβ signaling [200]. As such, understanding the
function of specific dimers and the hand-off from dimer to dimer remains of vital
importance. It is feasible that the induction of unique dimers in response to different
stimuli is critical in mediating the appropriate response to the microenvironmental
changes encountered by the cell. Depending on the relative proportion of dimers, cells
may proliferate, die, or migrate (Figure 1.13).
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Table 1.2: Phenotypes of AP-1 Genetically Modified Mice
Table showing the associated phenotypes of published knockout and knock-in studies
involving Jun and Fos proteins.
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Table 1.2
Phenotype of Knockout Mice
Gene

Phenotype

Tissues Affected

c-Jun

Embryonic Lethal (E12.5)[136]

Defects in heart and liver
development

JunB

Embryonic Lethal (E10)[137]

Placental Tissue

JunD

Male Sterility [145]

Testis

c-Fos

Lack osteoclasts[150, 151]

Bone

FosB

Nurturing defects[156]

Brain

FRA-1

Embryonic Lethal (E9.5)[146]

Placental Tissue

FRA-2

Death at Birth[160]

Cartilage and Bone

Phenotype of Knock-In Mice
JunB for c-Jun

Rescues embryonic lethality and
some transcriptional targets.
Mice die shortly after birth[140]

Heart

FRA-1 for c-Fos

Rescues phenotype[154]

None

JunB for FRA-1

Partially rescues phenotype[146]

None

Phenotype of Overexpression Mice
H2kb-cJun

None[144]

None

UbC-JunB

None[143]

None

H2kb-cFos

Osteosarcoma[144]

Bone

H2kb-FRA1

Increased Bone formation[149]

Bone

H2kb-FosB

None[144]

None

NSE-ΔFosB

Defects in Osteoclast and T-cell
Differentiation[158, 159]

Bone and Thymus

CMV-FRA2

Ocular defects[161]

Eye
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Figure 1.10: Structure of the JUN and FOS protein Family
Schematic diagrams representing conserved domains present within either the Jun or
Fos family of proteins. The percentage of similarity and identity is presented for each of
these conserved regions. Other critical regions are highlighted by name (Bzip domain,
degrons, etc.). Known sites of phosphorylation are highlighted by lollipops (green are
activating, red are inactivating, purple are localization, and white are unknown in
function).
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Figure 1.11: Role of AP-1 in Tumorigenesis
The hallmarks of cancer are commonly used to highlight the deregulation of normal
cellular processes in cancer. Interestingly, AP-1 has been shown to impact nearly every
proposed hallmark of cancer through the regulation of specific genes. Other hallmarks
have also been shown to induce AP-1 activity. Known AP-1 target genes and their role
in these hallmarks are presented in adapted figure from Hanahan and Weinberg[168].
Effects in green indicate increased expression or activation of pathways whereas red
indicates decreased expression or activity.
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Figure 1.12: Combinatorial Possibilities of AP-1 Dimers
Based on the dimerization properties of Jun and Fos proteins there are 18 potential
combinations for AP-1. 6 of these are “Jun:Jun” homodimers, whereas 12 are Jun:Fos
heterodimers. The total number of AP-1 dimer combinations can further expand based
on the inclusion of non-canonical dimers including ATF, MAF, CREB, and Smad
proteins.
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Figure 1.13: Model of AP-1 Response to Differing Stimuli
Hypothetical models of Jun and Fos protein expression in response to differing stimuli.
Studies have shown that depending on the stimulus the induction of Jun and Fos
proteins differs. This suggests that the specific induction pattern of different Jun and Fos
proteins may result in a different outcome in response to various stimuli. These
induction patterns may also regulate the hand-off from one dimer combination to
another, as the relative contribution of each dimer to the total of AP-1 shifts to mediate a
lasting transcriptional response.
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4. p53
4.1 Structure and Function
The TP53 gene located on chromosome 17 encodes the tumor suppressor p53.
This gene locus contains 11 exons, the first of which is non-coding [201]. The canonical
p53 (also called FLp53, p53α, or TAp53α) consists of 393 amino acids and contains 6
functional domains. These include 2 N-terminal transactivation domains (TAD1 and
TAD2), a proline rich domain, DNA binding domain, tetramerization domain, and a Cterminal regulatory domain [201]. Depending on the use of internal start sites and
alternative splice sites, the TP53 gene can encode at least 12 different variants of p53
(Figure1.14) [202, 203]. These variants can dramatically alter function through changes
in the normal domain structure of p53. For example, Δ40p53 utilizes an internal start
site within the full-length p53 sequence and this isoform lacks the first transactivation
domain, as well as the Mdm2 binding site that normally regulates stability. As a result,
Δ40p53 exhibits different transcriptional activity and stability as compared to p53α [204207].
Under normal cellular conditions, p53 is a critical regulator of progression through
the cell cycle and is activated in response to deviations from normal homeostasis [208].
In the absence of stressors, p53 is maintained at very low levels, primarily through the
regulatory effects of Mdm2 [209]. Mdm2 is an E3 ubiquitin ligase that regulates the
turnover of p53 protein by promoting the ubiquitination and degradation of the protein
[210]. This is accomplished through the binding of Mdm2 to p53 within TAD1. Induction
of cell stress, such as through DNA damage, results in activation of stress related
kinases ATR and ATM and promotes phosphorylation of p53 [211, 212]. Downstream
activation of Chk1 and Chk2 can further phosphorylate p53 [213]. These stress kinases
also phosphorylate Mdm2 interfering with degradation of p53 [214] (Figure 1.15). Once
p53 is stabilized it will oligomerize to form tetramers and bind to the promoters of specific
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targets, such as p21 or Puma, to promote either growth arrest and DNA repair or induce
apoptosis [208]. Increased p53 activity also results in upregulation of Mdm2 to form a
regulatory feedback loop to control p53 expression. As a result, the p53 response
exhibits pulsatile dynamics with cyclical peaks and valleys of p53 expression allowing for
multiple checks for lesions before re-entry into the cell cycle [215].

4.2 Loss of p53 function in Cancer
Loss of p53 function plays a major role in the development of most cancers and
can occur through a number of mechanisms. Destabilization of the p53 protein, such as
through E6 and E7 viral oncoproteins has been shown to play a major role in the
development of cervical cancer following infection with the human papilloma virus (HPV)
[216, 217]. Expression of these proteins is also commonly used in the process of
immortalizing normal human cells for in vitro study [218, 219]. Expression of other viral
proteins can also inactivate p53 including SV40 large T-antigen and adenovirus E1B
protein [220]. Likewise, overexpression of Mdm2 has been observed in several cancers
as a mechanism of decreasing p53 expression [221, 222]. Homologs of Mdm2, like
MdmX, can also act as negative regulators of p53 and are also upregulated in
neoplasms [223]. Methylation of the p53 promoter element can also drive loss of p53
expression [224-226]. Finally, loss of p53 function can occur through deletion, nonsense
mutations, and missense mutations [227]. The vast majority of these mutations occur
within the DNA binding domain of p53 and have long been thought to result in loss of
DNA binding capacity (Figure 1.16). In particular there are approximately 6 hotspots that
are consistently mutated including R175, G245, R248, R249, R273, and R282, all of
which are present in the DNA binding domain.
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Initially, it was postulated that tumor development required “two-hits” of tumor
suppressors for complete loss of function and tumor progression [228, 229]. While this
model holds true in some cases, as research has progressed exceptions to this rule
have been found. These genes exhibit a haploinsufficient phenotype, suggesting that
one functional allele fails to generate enough product to reach a normal threshold.
Several studies have demonstrated that p53 exhibits a haploinsufficient phenotype [230,
231]. As a result, p53 germline mutations result in significantly increased risks for the
development of cancer, both through haploinsufficiency and the increased likelihood of a
secondary hit of the remaining functional allele [232].

4.3 p53 as a gain-of-function oncogene
Missense mutations of p53 were long considered loss-of-function mutations that
promoted tumor progression by removing normal cellular checkpoints regulated by p53
through abrogation of p53’s DNA binding capacity. However, unlike most tumor
suppressors, p53 mutations are primarily single amino acid substitutions as opposed to
nonsense mutations that yield either a truncated protein or no product at all.
Explorations into the activity of p53 mutants have suggested that mutant p53 may
function as an oncogene in a gain-of-function manner (Figure 1.17) [233-238].
Early studies in mice found that the presence of a mutant p53 allele was not
equivalent to a p53 null allele [239]. Similarly, in the KPC mouse model of pancreatic
cancer, expression of mutant p53 results in a widely metastatic disease whereas p53
knockout mice exhibit a more localized disease [15]. This phenotype is also observed in
other mouse models of cancer [240, 241] While missense mutations alter the structure
and residues involved in DNA binding, several studies have demonstrated that mutant
p53 retains some DNA binding to strong p53 promoters like the p21 promoter[242].
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Interestingly, these mutants often lose the capacity to bind the promoter of the proapoptotic protein Bax, suggesting that mutant p53 preferentially promotes survival
signaling while impairing apoptosis. These mutations also result in gain-of-function
binding to new DNA elements in a structure dependent manner[237, 243].
Beyond alterations to the DNA binding properties, mutant p53 also exhibits
enhanced stability and increased expression is often observed within tumors. This
appears to be due in part to impaired regulatory feedback between Mdm2 and p53 [244].
Mutation of p53 also results in novel interactions with new partners to drive protumorigenic effects [245-247]. A subset of p53 mutants gain the ability to associate with
related family members p63 and p73 to inhibit growth suppression [248]. A number of
other mutants have also shown the capacity to interact with the transcription factor SP-1
to drive expression of SP-1 genes [249, 250]. Other studies have implicated mutant p53
in alterations to DNA synthesis and proliferation, chemoresistance, acquisition of stem
cell characteristics, and induction of angiogenesis [251-254]. As a result, reactivating
wildtype p53 function through the refolding of mutant p53 is a widely explored
therapeutic option [255-258].
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Figure 1.14: Structure of Full-Length p53 and its Variants
A schematic diagram presenting the domain structure of full-length p53 and its variants
from internal start sites or alternative splicing. Δ variants arise through the use of
internal ATG start sites within the amino acid sequence, whereas β and γ variants arise
from alternative splicing of C-terminal exons. As a result, the TP53 gene can give rise to
12 unique forms of p53.
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Figure 1.15: p53 Response to DNA Damage
In response to DNA damage, ATM is activated and phosphorylates Chk1. Both Chk1
and ATM can phosphorylate p53 resulting in stabilization of the protein. ATM also
phosphorylates Mdm2 to inhibit its activity and further stabilize p53. P53 then can
induce transcription of either survival/growth arrest genes like p21 or induce cell death
pathways through induction of pro-apoptotic proteins. Increased p53 activity also drives
increased expression of Mdm2 in an autoregulatory manner to turn off p53 signaling.
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Figure 1.16: Mapping of p53 Mutations
Schematic representation of known mutations in p53 in pancreatic ductal
adenocarcinoma. Length of each lollipop indicates the relative proportion of mutation.
Hotspot mutations typically occur within the DNA binding domain of p53, whereas
mutations in other domains are uncommon. Data were collected from cBioportal and
from the TCGA.
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Figure 1.17: Mechanisms of Mutant p53 Gain-of-Function Effects
Mutant p53 has been proposed to gain oncogenic potential through a number of different
mechanisms. A) Binding to p63 and p73 and inhibiting transcription of downstream
targets. B) Association with novel transcription factor partners to alter expression of
their targets. C) Binding of novel DNA elements in a structure specific fashion. D)
Association with novel non-transcriptional partners.

Figure 1.17

Inhibition of p63/73 gene targets
mt p53

Gain of novel interaction partners
mt p53

p63/73

Protein X

mt p53

mt p53
TF

Co-regulation of other
transcription factor targets

mt p53

Structure specific DNA binding

62

5. Statement of Research
Based on the known role of MUC1 as an integrator of cellular signals and known
associations with both AP-1 and p53, we sought to explore how MUC1 alters the
formation and regulation of these transcriptional complexes. We focused upon how the
MUC1 cytoplasmic tail is capable of integrating multiple signals to initiate appropriate
downstream signaling. Furthermore, we investigated how expression of MUC1 impacts
AP-1 with special focus on roles in migration, invasion, and metastasis in pancreatic
cancer. Lastly, we examined how the mutational status of p53 can influences its
association with the cytoplasmic tail of MUC1 and the potential influence of gain-offunction effects.
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Chapter II: Materials and Methods
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Antibodies
The anti-MUC1 antibody CT2 was generously provided by Dr. Sandra J Gendler or
ordered from Abcam (ab80952). Phospho-specific antibodies against the MUC1
cytoplasmic tail were previously generated within the lab. Antibodies against c-Jun and
phosphoSerine73 c-Jun were obtained from Abcam (ab31419, ab32447). Antibodies
against phosphoFRA-1, phospho-c-Fos, ERK, and phosphoERK were purchased from
Cell Signaling (#5841, #5348, #9107, and #4377 respectively). Antibodies measuring the
DNA damage response (pChk1, pChk2, phospho-p53, PUMA, and p21) were also
obtained from Cell Signaling (#9947S, #12450S, and #2947S respectively). Antibodies
against Cyclin D1 and Cyclin A were purchased from Cell Signaling (#2926 and #4656
respectively). FRA-1, c-Fos, and H2B were obtained from Santa Cruz (sc-28310, sc8047, sc-8650) and ATF2 from Novus Biologicals (H00001386-M02). β-actin, p53 (DO1), and Flag (M2) antibodies were obtained from Sigma Aldrich.

BET Inhibitor Treatments
BET inhibitors JQ-1 and OTX015 were purchased from SelleckChem (Cat.No
S7110 and S7360). Inhibitors were suspended in DMSO and stored as aliquots until
use. Cells received either inhibitor treatment or DMSO control at the indicated doses.
Cells were only treated once per experiment.

Cell Culture
Panc1, Colo357, and AsPC-1 cells were obtained from American Type Culture
Collection and S2013 cells were obtained from the originator of the line [69].
S2013.Neo and MIF were generated as previously described [102]. Panc1.MUC1 and
Neo were generated from stable transfection of pSIN-ires-neo using lentiviral
transduction. Panc1.MUC1-FRA1, Panc1.Neo-FRA1, S2013.Neo-FRA1, and
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S2013.MIF-FRA1 lines were generated by stable transfection of pLVX.puro using
lentiviral transduction. FRA-1 knockdown was performed using the previously
characterized shRNA TRCN0000019539 [259] or scrambled control purchased from
OpenBiosystems.

Cells were selected in Dulbecco’s modified Eagle’s medium

(DMEM) supplemented with 4 µg/ml Puromycin, 10% fetal bovine serum (FBS), and 1X
HyClone penicillin/streptomycin mix (100 U/ml penicillin and 100 µg/ml).
Colo357, Panc1, and HPDE inducible p53 cell lines were generated by
sequential lentiviral transduction of pLVX.Tet-ON, and pLVX.Tight-puro generously
provided by Dr. Angie Rizzino, followed by sequential selection in DMEM supplemented
with 1000 µg/ml G418 or 4 µg/ml Puromycin. Once selection had occurred cells were
maintained in 10% DMEM supplemented with HyClone pen/strep mix. Cells were
maintained at 37°C in a humidified environment with 5% CO2.

Cell Cycle Analysis
Cell cycle analysis was performed using the propidium iodide flow cytometry kit
purchased from Abcam (ab139418). Briefly, supernatant was removed and adherent
cells were trypsinized and removed from plate by rinsing with original supernatant. Total
cells were counted and 1 million cells were pelleted and fixed with 70% EtOH. After all
time points were collected, cells were prepared for flow cytometry. Fixed cells were
pelleted and washed 2X in 1X PBS. Cells were then resuspended in 400 µl 1X
Propidium Iodide + RNase Staining Solution. Cells were incubated in the dark for 30
minutes at 37 °C before being taking to the UNMC flow cytometry core for analysis.
Average percentages of cells in each phase were then plotted for each treatment group.

Chromatin Shearing and Chromatin Immunoprecipitation (ChIP)
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A 15 cm dish of cells was fixed in 1% formaldehyde at room temperature for 10
minutes according to the MagnaChIP protocol (Millipore). After fixation cells were
quenched with 1X glycine from kit. Cells were washed and collected in 1X PBS
containing protease inhibitors. Cells were than pelleted and supernatant removed. 500
µl of cell lysis buffer was added for each 15 cm dish. Cells were incubated on ice for 15
minutes before being pelleted again. 500 µl of nuclear lysis buffer was added and lysate
was aliquoted into Covaris AFA sonication tubes. DNA shearing was done for 6 minutes
on the Covaris S2 sonicator with 2% duty cycle, 3 intensity, and 200 cycles per burst.
Shearing was assessed using agarose gel and chromatin stored at -80°C until use.
Chromatin immunoprecipitation was performed according to MagnaChIP (Millipore)
protocol using 5 µg FRA-1 (sc-605) antibody or IgG control per 50 µl chromatin. Eluted
DNA was analyzed by qRT-PCR and compared to both input and IgG controls.

Co-immunoprecipitation
Cells were grown to 80-90% confluence and lysed in co-immunoprecipitation
buffer (50 mM Tris-Cl, 150 mM NaCl, 0.5% NP40, pH 8.0) in the presence of protease
and phosphatase inhibitors (ThermoFisher 78440). Buffer was adjusted to 300 mM
NaCl to promote extraction of nuclear proteins. Lysates were incubated on ice for 30
minutes and insoluble debris removed by centrifugation at 16,000g. 300 µl of lysate was
incubated with Protein G beads (ThermoFisher 1003D) and antibodies against the
protein of interest or an IgG control at 4°C for 2 hours to form complexes. For p53-Flag
pulldown, M2 agarose beads were used instead of Protein G. Beads were washed 3X
with Co-IP wash buffer (50 mM Tris-Cl, 150 mM NaCl, 0.1% NP40) and proteins eluted
by boiling in SDS sample buffer. Each co-immunoprecipitation study was performed
multiple times to ensure reproducibility.
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Construct Generation
FRA-1 constructs were designed by PCR amplification of FRA-1 cDNA
purchased from OpenBiosystems. Primers used were designed for placement of a HAepitope tag on the C-terminus of FRA-1. Amplified fragments were then restriction
digested and ligated into pLVX.puro vector for lentiviral transduction. DNA sequencing
of the plasmid confirmed appropriate sequence.
Inducible p53 constructs were designed by PCR amplification of cDNA from
OpenBiosystems and a C-terminal 3X-Flag tag added through PCR. Amplified products
were cloned into the pLVX.Tight-puro construct from Clontech. Specific p53 mutants
were generated using the site-directed mutagenesis kit from Agilent and all mutants
were confirmed by DNA sequencing.
Homologous arm constructs for CRISPR mediated fusion protein knock-ins were
designed using primers specific for regions upstream and downstream of the predicted
CRISPR cut site. Amplicons were approximately 1.5 kb. PCR amplification of these
regions was performed following isolation of genomic DNA from cell lines. Amplicons
were then cloned into original AAV vector provided by Dr. John Albeck.

DNA Damage Studies
Cells were exposed to either UV or X-ray irradiation. X-ray irradiation was
performed using RS-2000 irradiator in the Biological Irradiation Core and cells were
treated with the indicated doses. UV damage was induced by exposure to DNA gel box
for 5 minutes. Following DNA damage cells were returned to the incubator for 1 hour
before lysis and examination of DNA damage response by western blot analysis.

Doxycycline Treatment of Inducible Cell Lines
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Fresh doxycycline was prepared in autoclaved water and stored as aliquots until
use. Cells were primarily treated with 1 µg/ml doxycycline unless otherwise indicated.
Cells were treated for 24 hours prior to analysis of p53 expression and downstream
effects except for long-term studies. For studies longer than 24 hours, media was
replaced with fresh doxycycline containing media every 24 hours to retain expression of
p53 as doxycycline degraded.

Immunoblotting
Proteins were transferred from gels to Immobilon-FL PVDF membrane using the
Bio-Rad transfer system at 100V, 0.3 A, for 70 minutes. Membranes were rinsed in 1X
PBS then blocked for 1 hour in a 1:1 mixture of 1X PBS and Licor Blocking buffer.
Primary antibodies were incubated for 1 hour in 0.1% PBST:Licor buffer. All primary
antibodies were used at a concentration of 1 µg/ml. Membranes were washed three
times with 0.1% PBST. Secondary antibodies were conjugated to IrDyes (Licor) and
incubated for 1 hour in the dark in 0.1% PBST/Licor buffer with 0.01% SDS to reduce
background. Blots were washed three more times, rinsed with 1X PBS, and visualized
using the Odyssey Imaging System.

Immunohistochemistry
Slides containing primary pancreatic tumor, liver metastases, or uninvolved
pancreas were obtained from the UNMC Rapid Autopsy Program. Staining was
performed using the Dako Envision+ kit (K4006) with a hematoxylin counter-stain. AntiFRA-1 (sc-28310), Anti-ZEB1 (ab180905), Anti-slug (ab27568) and IgG control were
used at a concentration of 10 µg/ml. Following staining, slides were mounted and
imaged.
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Invasion and migration assays
Assays were carried out using matrigel invasion plates or control migration plates
from BD Biosciences (#354480 and #354578 respectively). Cells were grown to
approximately 60% confluence and serum starved 24 hours prior to assay. Treated cells
received a 2-hour pretreatment of 10µM U0126 (Sigma). Prior to plating, matrigel matrix
in invasion plates was rehydrated for 2-4 hours with serum free media at 37°C, migration
plates required no pre-treatment. 100,000 cells per well were plated for invasion assays
and 25,000 cells per well for migration assays. Chemoattractant in the lower well was
10% FBS containing DMEM. Cells were incubated at 37°C for 24 hours, then inserts
were washed and stained using the DiffQuick staining kit. Membranes were dried and
mounted on slides for quantification. Each experimental group was examined in two
independent experiments with each group plated in triplicate. Stastical analysis was
performed using 2-tailed student’s t-test.

KPC MUC1 knockout mice and cell lines
KPC mice were bred at UNMC to carry the PDX-1-Cre transgene [260], the LSLKRASG12D knock-in mutation [261] and the LSL-Trp53R172H knock-in mutation [262]. In
the context of the KPC background, mice were bred to the Muc1 knockout mouse [263]
to generate KPC mice that express Mucin-1 (KPC WT) or are deficient in Mucin-1
expression (KPC KO). Cell lines were derived from primary tumors of each genotype
and utilized for further analysis. Cell lines were collected by collagenase digestion of
primary tumors and fibroblasts removed through selective trypsinization of the cells over
multiple passages.

Lentiviral Generation
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Lentivirus was generated through transfection of 293A cells with 3:1:4 ratio of
packing vectors psPAX2 and pMD2.G along with the appropriate lentiviral vector
containing our sequence of interest. Transfection was performed using the X-fect
protocol from Clontech. Lentivirus was collected at 24, 48, and 72 hours posttransfection. Virus containing media was passed through a 0.45 µm SFCA filter and
polybrene (6 µg/ml) added to the filtered media. Viral media was then applied to
transduced cells.

Methylene Blue Proliferation Assay[264]
2,000 cells were plated in 6 wells of a 96-well plate for each cell line. One plate
was used for each time point measured (0, 24, 48, 72, and 96 hours [also 120 and 144
hours in Colo357 studies]). After each time point cells were fixed with formalin and kept
at 4° until all time points were taken. To generate the 0 hour time point the cells were
allowed to adhere for two hours and then immediately fixed. Following fixation cells
were stained for 30 minutes with 1% methylene blue in 0.01M borate buffer (pH8.5).
Plates were rinsed 4 times in 0.01M borate buffer and the dye eluted with 100 µl of 1:1
ethanol and 0.1M HCl. The absorbance at 650 nm was measured with a plate reader
and results normalized to background. 2-way ANOVA was used to assess differences in
proliferation between multiple cell types and treatment groups.

Orthotopic Mouse Studies
All mouse studies were performed according to UNMC IACUC specifications.
150,000 tumor cells were injected orthotopically into the pancreas of nude mice.
S2013.Neo and MIF cell lines and their FRA-1 knockdown counterparts were utilized for
the study. Groups consisted of 12-13 mice for a total of 50 mice overall, all mice were
female. Tumors were allowed to develop for 30 days, at which time mice were sacrificed
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and tumors measured. Presence of ascites and metastasis was initially assessed based
on gross observation during necropsy. Tissues for each metastatic site and primary
tumor were formalin fixed. The UNMC tissue sciences core facility cut and stained H&E
slides for each sample in the experiment. Metastases were confirmed by microscopy
before final scoring. Statistical analysis of differences in tumor growth was assessed
using ANOVA and Bonferroni method for multiple comparisons.

Phosphatase Assay:
MUC1 wild type mouse stomach was lysed into T-Cell Protein Tyrosine
Phosphatase buffer (50 mM Tris-HCl, 100 mM NaCl, 2 mM Na2EDTA, 5 mM DTT,
0.01% Brij35, pH 7.5) supplemented with protease inhibitor cocktail tablet (Roche) using
a 27 gauge needle for full lysis. Lysates were divided evenly into 2 microcentrifuge
tubes with 1 receiving 20 µl (200 U) T-Cell Protein Tyrosine Phosphatase (New England
Biolabs) and the other receiving a phosphatase inhibitor to reduce active phosphatase
activity in the whole lysate. Samples were incubated at 30°C in a water bath for 3 hours
to yield maximal dephosphorylation. Samples were then buffer exchanged into 2DXtract buffer using Zeba desalting columns and analyzed with 2D gel electrophoresis.

Proximity Ligation Assay (PLA)
All PLA reagents used were from Duolink PLA kit. Cells were grown in 12-well
plates on poly-lysine coated slides. Cells were fixed with 4% PFA supplemented with
120 mM sucrose. The reaction was quenched by removal of PFA and addition of 0.1 M
glycine for 5 minutes followed washes with 1X PBS. Cells were permeabilized using 500
µl of 0.15% Triton-X-100 with 1% BSA in 1X PBS for 15 minutes then blocked with 1
drop of blocking solution for 30 minutes at 37°C. Blocking solution was removed and
coverslips incubated with the primary antibodies in antibody diluent (1:200) overnight at
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4°C. After incubation, coverslips were washed three times with PLA wash buffer A for 5
minutes. PLA secondary probes were added and incubated at 37°C for 1 hour in the
dark. Coverslips were washed twice more with PLA wash buffer A and ligation reaction
mix was added to the coverslips for 30 minutes at 37°C. After two more washes in
buffer A the amplification-polymerase solution was added for 100 minutes at 37°C.
Coverslips were washed twice in 1X PLA wash buffer B then once in 0.1X buffer B.
Coverslips were mounted with Fluoromount G with DAPI. Results were visualized with
confocal microscopy and the interactions were quantified using Blobfinder. All
experimental groups were performed in quadruplicate and multiple independent fields
per slide were used for quantification. Statistical analysis was performed by 2-tailed
student’s t-test.

Purification of Recombinant MUC1
Recombinant expression of MUC1 was induced in C41 or C43 E.coli through
transformation with the pGEX4T-1 plasmid. The full-length cDNA sequence of the
MUC1 C-terminus was optimized for E.coli expression before being cloned into this
vector to generate a C-terminally tagged GST-MUC1 construct. GST-purification kit
was ordered from Clontech (Cat# 635619) and purification of recombinant protein was
performed according to the provided protocol. Pulldown of recombinant MUC1 was
confirmed by western blot analysis of elution fractions.

R programming
All applications involving R programming language were performed using
RStudio. Heatmaps were generated in R for all Immunohistochemistry experiments.
Hierarchical clustering was also performed using R programming language to generate
the distance scores and cluster the individual tumors utilized in Bailey, et al[18].
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Individual box plots for each gene were also designed using R programming to cluster
each tumor into it’s identified subtype and plot the normalized RNA-seq expression
values.

RNA Isolation, RT-PCR, and RNA-seq
Cells were grown to 80-90% confluence on 15 cm dishes, rinsed with 1X PBS
and RNA isolated using the Qiagen RNeasy kit. For inducible p53 studies, cells were
treated with indicated doses of doxycycline for 24 hours prior to RNA isolation. Isolated
RNA was aliquoted and stored at -80 until use. RNA was converted to cDNA using the
Verso cDNA kit (ThermoFisher) and cDNA was stored at -20 until use. All RT-PCR
primers were obtained from PrimerBank. RT-PCR for each primer set was performed in
triplicate and Sybr Green was used for signal detection. Fold change was calculated
using the ΔΔCt method and converted to log2fold change or normalized to 18s rRNA for
plotting multiple genes on the same graph. For single comparisons statistical
significance was assessed by student’s t-test. For multiple comparisons 2-way ANOVA
was used. For RNA-seq assays, RNA was collected from 3 biological replicates using
the Qiagen RNeasy kit and submitted to the UNMC sequencing core for library
preparation and sequencing using the Illumina HiSeq2500. Results were analyzed using
tophat/cutdiff and edgeR analysis programs by the UNMC bioinformatics core.
Differentially expressed genes were then run through Qiagen’s Ingenuity Pathway
Analysis to identify cellular pathways that were altered between cell lines[265].

Subcellular Fractionation
Cytoplasmic and Nuclear fractions were obtained using the nuclear fractionation
protocol from Abcam. Cells were grown to 80-90% confluence and lysed into Buffer A
(10mM HEPES, 1.5 mM MgCl2, 10mM KCl, 0.5mM DTT, and 0.5% NP40) and then
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incubated on ice for 30 minutes. Lysates were spun down at 3000 rpm for 10 minutes at
4°C to pellet nuclei. The supernatant was removed as the cytoplasmic fraction and the
nuclear pellet was washed 3 times in Buffer A to remove potential contaminants. The
nuclear pellet was lysed in Buffer B (5mM HEPES, 1.5mM MgCl2, 0.2mM EDTA, 0.5mM
DTT, 26% glycerol, supplemented with 300mM NaCl added fresh). To ensure lysis, the
nuclear pellet was passed through a 25-gauge needle and the lysates incubated on ice
for 15 minutes. Lysates were then spun down at 16,000g for 15 minutes to pellet
insoluble debris. The supernatant was collected as the nuclear fraction. Fraction purity
was assessed by western blotting with an antibody to Histone 2B.

2D gel electrophoresis
Cells were grown in 150 mm dishes until approximately 90% confluent. Cells
were washed with 1X PBS and lysed with 8M urea/thiourea containing 2D-Xtract buffer
(G-Biosciences) supplemented with complete protease and phosphatase inhibitor
(ThermoScientific) and removed from the dish by scraping. Mouse tissues were
homogenized using dounce homogenizers directly into 2D-Xtract buffer supplemented
with protease and phosphatase inhibitors. The resulting lysates, cells and tissue, were
then alkylated with 5 µl/ml N, N-dimethylacrylamide and placed on a rotator for 20
minutes at room temperature. Alkylated samples were quenched with DTT to a final
concentration of 200 mM, and centrifuged at 13,000 rpm for 30 minutes to pellet
remaining debris. Protein concentration was determined by Bradford analysis and
diluted to a loading concentration of 175 µg/ 155 µl, with 1 µl of the appropriate pH
ampholytes (Invitrogen 3-10 or 4-7) and 1 µl 0.25% Bromophenol blue. 155 µl of sample
was loaded into each lane with the IPG Zoom strip and allowed to rehydrate the gel strip
for a minimum of 2 hours. Following rehydration, loading wells were removed and filter
paper saturated with 600 µl DI water was affixed to the designated location. Zoom tray
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was loaded into the running apparatus and the outer well filled with 600 ml DI water.
Isoelectric focusing was performed per manufacturers specifications (Zoom IPG runner,
Invitrogen). Following first dimension electrophoresis, IPG strips were equilibrated in 10
ml 1X SDS sample buffer with 100 mM DTT for 12 minutes then with a 12 minute
equilibration in 10 ml 1X SDS sample buffer with 232 µg iodoacetamide. IPG strips were
loaded into 4-12% Bis-Tris Zoom Gels, IPG well (Invitrogen) and sealed with 0.5% MES
or MOPS agarose, depending on second dimension running buffer. Gels were loaded
onto the Invitrogen running apparatus with MES or MOPS running buffer depending on
the molecular weight of proteins of interest and run at 175 V for 80 minutes.
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Chapter III: Post-translational Modification of the MUC1
Cytoplasmic Tail and Its Splice Variants
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1. Key Findings
•

MUC1 exists in an extensively phosphorylated state in normal mouse pancreas

•

Alterations to the surrounding environment or transformation alters the posttranslational modification of MUC1

•

MUC1.CT is N-glycosylated and this form appears to translocate to the nucleus

•

Processing of MUC1 does not appear to involve TACE, however, another selfcleaving module may be present within the MUC1.CT

•

MUC1 splice variants exhibit extensive phosphorylation suggesting a functional
role in cell signaling
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2. Introduction
The cytoplasmic tail of MUC1 is postulated to act as a sensor of the extracellular
environment; integrating information from the surroundings and propagating intracellular
signaling events to drive cellular responses [26]. While numerous studies have
demonstrated specific phosphorylation events within the cytoplasmic tail and the
corresponding impact on cell signaling, no studies have evaluated the global
phosphorylation status of MUC1 [77-79, 82, 100, 104, 266]. The cytoplasmic tail of
MUC1 contains 21 potentially phosphorylated residues. This allows for a potential of
more than 2 million combinatorial patterns of phosphorylation. This patterning may
explain the capacity of MUC1 to alter many distinct pathways, in many instances
involving phosphorylation of the same residue [20, 26, 77, 100].
Phosphorylation of MUC1 is thought to be critical for it to translocate to the
nucleus where it functions as a transcriptional co-regulator in association with
transcription factors, such as p53 and β-catenin [26]. Interestingly, the precise fragment
of MUC1 that translocates within the nucleus remains unknown. It has been proposed
that MUC1 may potentially undergo a proteolytic cleavage event, similar to Notch
signaling, and only the cytoplasmic tail may go to the nucleus [267]. Another possibility
is the endosomal transport of MUC1 into the nucleus, similar to the mechanism of ErbB2
translocation [90].
Further adding to the complexity of signaling through MUC1 is the presence of
several splice variants [268]. In many instances, these splice variants retain at least a
portion of the cytoplasmic tail, potentially allowing for distinct signaling mechanisms.
The C-terminal subunit of MUC1 also contains a consensus sequence for N-linked
glycosylation. These glycosylation sites may be critical mediators of interactions with
various signaling partners in the extracellular compartment.
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Given the role of MUC1 in oncogenic signaling, we sought to explore the range of
post-translational modifications on MUC1. Presumably, modification of these sites
allows for MUC1 to relay a wide array of signals into the cell. To assess these
modifications, we utilized 2D gel electrophoresis, as well as phosphorylation specific
antibodies in an attempt to map the patterns observed on MUC1. We performed
additional studies evaluating the potential for N-glycosylation of the MUC1.CT, as well as
the possibility of proteolytic cleavage of the cytoplasmic tail. We found that MUC1 exists
in an extensively phosphorylated state, and that this phosphorylation can be impacted by
cellular transformation or stimulation with different factors. Furthermore, MUC1 appears
to translocate to the nucleus as 3 distinct forms, one of which is N-glycosylated. These
forms are apparently independent of proteolytic cleavage by ADAM17; however, in vitro
studies suggest that self-cleavage effects may occur within the cytoplasmic tail as a
result of chemical reactions involving the cysteine residues of the cytoplasmic tail.
Furthermore, MUC1 splice variants are also extensively phosphorylated suggesting
potential signaling roles for these variants in addition to full-length MUC1.

3. Results
MUC1.CT is Extensively Phosphorylated in Response to Environmental Factors
The C-terminal subunit of MUC1 (MUC1.CT) contains a wide array of potential
post-translational modification sites. In particular, the cytoplasmic tail contains several
serine, threonine, and tyrosine residues (Figure 3.1A). To assess the post-translational
status of MUC1, we performed 2D gel electrophoresis to identify changes in predicted
size or isoelectric point in normal mouse pancreas and in KPC tumors. We observed the
presence of 3 distinct bands of approximately 25, 20 and 15 kDa deviating from the
predicted molecular weight of 17 kDa of the 158 amino acid, MUC1.CT. This was true
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for both normal mouse pancreas and KPC pancreatic tumors. We also observed
significant deviations from the predicted isoelectric point of 6.4. Phosphorylation is
predicted to cause a decrease in the observed isoelectric point [269]. To test whether
these deviations were the result of phosphorylation, we treated mouse pancreas extracts
with 200 U T-cell tyrosine phosphatase for 3 hours at 30°C and repeated the 2D gel
analysis. Treatment resulted in a shift of isoforms from an apparent PI of 4.0-4.6 back
towards a range of 4.9-6.0, approaching the predicted isoelectric point of 6.4, though this
shift was incomplete, suggesting the presence of additional modifications of serine and
threonine residues on the MUC1.CT (Figure 3.1B). Interestingly, KPC tumors exhibited
higher levels of the lower isoelectric point forms than normal mouse pancreas,
suggesting hyperphosphorylation in these tumors.
To further assess potential phosphorylation events of MUC1.CT, we performed
western blots of normal mouse pancreas utilizing phosphospecific antibodies raised
against unique MUC1 phosphoepitopes. We observed positive results with antibodies
against a number of sites, suggesting that MUC1.CT is indeed extensively
phosphorylated at a variety of sites (Figure 3.1C). In addition, the different gel mobilities
shown in 3.1.C suggest that the rather broad bands observed with antibodies against the
MUC1CT (e.g. Figure 3.1.B) are comprised of isoforms of MUC1CT that are differentially
phosphorylated at multiple sites in different combinations. To confirm that receptor
tyrosine kinases and other stimuli signal through MUC1CT, we evaluated the effect of
stimulating MUC1 expressing cells with EGF. Stimulation of cells with either FBS or
EGF resulted in differential patterning of MUC1 phosphorylation events, suggesting that
different stimuli promote different phosphorylation patterns of MUC1.CT (Figure 3.2).
MUC1.CT is N-glycosylated and Present in the Nucleus
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The juxtamembrane portion of the extracellular domain of the MUC1.CT contains
a consensus site for N-glycosylation (NXS/T). Previous studies have suggested that
MUC1.CT is N-glycosylated at this site [270]. We sought to confirm the presence of Nlinked glycosylation at this site. Furthermore, we wanted to identify whether this form
was present within the nucleus, given the previously reported finding that the
extracellular part of β-dystroglycan can traffic to the nucleus [271]. We performed
western blot analysis of normal mouse pancreas extract following treatment with the
glycosidase PNGase F (Figure 3.3A). PNGase F treatment resulted in a decrease in the
apparent molecular weight of the 25 kDa band to the 20 kDa band, indicating that
MUC1.CT is N-glycosylated. To test whether this form is present within the nucleus, we
performed subcellular fractionation of S2013.Neo and MIF cells (Figure 3.3B) and
treated the nuclear fraction of S2013.MIF cells with PNGase F, followed by western blot
analysis. PNGase treatment induced a shift of MUC1.CT from 25 to 20 kDa indicating
loss of N-glycosylation and suggesting that this form is present within the nucleus
(Figure 3.3C). This supports the hypothesis that the 25 kDa band of MUC1 seen in
these experiments contains the C-terminus with N-glycosylation, whereas the 20 kDa
band contains non-glycosylated forms of MUC1.CT.

MUC1.CT Processing is Unaffected by a TACE Inhibitor
There have been reports of putative cleavage sites within the C-terminal portion
of MUC1 for the ADAM17 protease, also called TACE [272]. This cleavage results in
truncation of the predicted 58 amino acid extracellular domain of MUC1CT. As we had
previously identified the 25 and 20 kDa bands of MUC1.CT, we sought to examine
whether cleavage by TACE was responsible for the formation of smaller bands, including
the 15 kDa band. We treated S2013.MIF cells with the TACE inhibitor, TAPI-2, at
increasing doses for 12 or 24 hours and monitored the processing of MUC1 by western
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blot analysis (Figure 3.4). We observed no significant differences in any of the MUC1
bands detected by CT2. This suggests that processing by TACE is not responsible for
the 15 kDa form of MUC1.CT.
The cysteine residues of MUC1.CT have been suggested to critically regulate a
number of processes, including dimerization. Interestingly, several studies have shown
nucleophilic chemical reactions within proteins resulting in self-cleavage events (Figure
3.5A). These excised segments are termed inteins and the cleavage events caused by
this chemical reaction can be catalyzed by the addition of reducing agents [273]. To
examine the potential dimerization of MUC1 in vitro we have purified recombinant MUC1
from E.coli cells and examined the properties under reducing or non-reducing conditions.
Under non-reducing conditions, we observe an approximately 40 kDa band consistent
with a dimer of MUC1. Interestingly, we have observed in initial studies with
recombinant MUC1.CT that the presence of DTT results in formation of a cleavage
fragment of approximately 15 kDa and this is absent in non-reduced conditions,
suggesting the possibility of a self-cleavage event involving the cysteine residues of
MUC1 (Figure 3.5B). Future studies using cysteine mutants may help to confirm this
possibility, though serine residues have also been shown to be involved in this type of
cleavage.
MUC1 Splice Variants are Extensively Phosphorylated
The MUC1 gene contains 7 exons and can be alternatively spliced into a wide
variety of alternative products [268]. Many of these variants retain the cytoplasmic tail
suggesting the possibility for differential signaling depending on the splice variant. While
the signaling capacity of MUC1 has been well studied, the potential for signaling through
the tail of variants has not been explored in depth. To assess the potential
phosphorylation of MUC1 splice variants we performed 2D gel analysis of recombinant
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X, Y, and SV3 splice variants expressed in HPNE cells (Figure 3.6A). Western blots of
the different isoforms show distinct changes in molecular weight for each isoform.
HPNE-mock tranfected cells showed no specific bands. Similar to the standard form of
MUC1, we observed significant deviations to the left of the predicted isoelectric (Figure
3.6B), suggesting that these MUC1 splice variants can be extensively phosphorylated
and suggesting that they may play a role in cellular signaling.

4. Discussion
The transmembrane mucin MUC1 plays a critical role in tumorigenesis through
the integration of microenvironmental signals and induction of downstream signaling
cascades to promote cellular responses and adaptation to changes in the extracellular
microenvironment [26, 43, 81, 83]. We propose that MUC1CT serves as a node to
integrate morphogenetic signals from a number of diverse networks, in part through its
capacity to receive multiple differential phosphorylation events. A number of studies
have demonstrated that phosphorylation of specific residues in the MUC1 cytoplasmic
tail are critical to drive its association with signaling factors and transcription factors;
however, until this report, no studies have evaluated the global phosphorylation status of
MUC1 [77, 100, 105, 274]. The studies reported here demonstrate that MUC1 exhibits a
wide array of modifications, including potentially 10 or more phosphorylation events
within the cytoplasmic tail. The fact that many of these modifications occur within the
normal pancreas support the hypothesis that phosphorylation of MUC1 contributes to
normal signaling in cells, and the finding that this pattern is significantly altered in cancer
supports the hypothesis that this biological process is co-opted and modified by
malignant processes in tumor cells.
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Most studies have focused on tyrosine phosphorylation of the MUC1CT as a
major player in MUC1 signaling. Our results show that tyrosine phosphorylation is
prominent in normal and malignant pancreatic cells; however, treatment with tyrosine
phosphatase does not remove all modifications, suggesting that a number of serine and
threonine residues are also phosphorylated. Preliminary western blot analysis of MUC1
using phosphospecific antibodies support this hypothesis, though the absolute specificity
of these antibodies has not been extensively validated. Interestingly, we found
significant alterations in the global patterns of phosphorylation by stimulating cells with
different growth factors, supporting the concept that MUC1 contributes to the integration
and relay of information about the cytokine status and other factors from surrounding
environment. Malignant transformation also results in hyperphosphorylation of the
cytoplasmic tail, suggesting alterations in signaling pathways during the progression to
malignancy. Based on these results, it is likely that the combinatorial pattern of the
phosphorylated residues is critical for initiating or regulating distinct downstream
responses. With the 22 potential sites of phosphorylation, there are more than
2,000,000 potential phosphorylation patterns, allowing for specific integration of multiple
signals.
We also explored potential modifications other than phosphorylation of the
cytoplasmic tail. Previous studies have shown that MUC1 contains a consensus site for
N-linked glycosylation within the C-terminal subunit, which appears to be N-glycosylated
[270]. We confirmed this finding in our studies and provide evidence that this form of
MUC1 can traffic to the nucleus. Similar studies have shown this effect with βdystroglycan, which has a general structure similar to MUC1 [271]. While these studies
are preliminary and perhaps controversial, the N-glycosylation of MUC1 has been
reported to regulate its interaction with EGFR [270, 275]. Association of MUC1 and
EGFR has also been shown to promote its nuclear translocation, suggesting the
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possibility that these signaling complexes are transported via an endosomal mechanism
that would allow translocation of both extracellular and intracellular portions of
MUC1.CT. Further studies using additional methods of distinguishing protein trafficking
and improved methods of cellular fractionation will help to address these questions.
We and others have found that the C-terminal portion of MUC1 exists as at least
3 distinct forms. While we have postulated that two of these forms are full-length
MUC1.CT either with or without N-glycosylation, to date the smallest form seen
commonly by gel electrophoresis has not been identified. We tested the hypothesis that
these forms were the result of proteolytic cleavage by the TACE protease, but found no
effect using a specific inhibitor, suggesting that this smaller form may result from
cleavage from an unidentified protease or may represent a distinct variant. Preliminary
biochemical studies of recombinant MUC1.CT raise the possibility that this smaller form
may be the result of a self-cleavage event involving nucleophilic reactions of cysteine
residues; however, validation of this hypothesis requires further study. These in vitro
studies also suggest that MUC1 can readily exist as a dimer, whether this occurs in vivo
remains controversial. Use of cysteine mutants may help to validate these studies,
though serine residues can engage in intein cleavages as well. Mass-spectrometry
identification of the fragment may assist in the identification of critical residues and
determination of whether any excision of internal residues actually occurs.
Interestingly, 2D gel analysis of known MUC1 splice variants showed extensive
phosphorylation similar to canonical MUC1. As these variants exhibit alterations in the
extracellular domains, they may propagate signals differently than full-length MUC1.
This may also account for the diverse phenotypes associated with MUC1 expression.
These findings also require additional study.
The studies reported in this chapter suggest that the C-terminal subunit of MUC1
is a dynamic structure, driving downstream signaling in part by conducting and
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integrating signals from growth factor receptors and other factors in the surrounding
environment. Future studies examining the specific residues that are phosphorylated
under given conditions should provide further insight into the specific nature and
integration of these signals. For example, some phosphorylation events may require
previous phosphorylation to create docking sites for other kinases, which may contribute
to our observation of widely different patterns of phosphorylation. Better understanding
of how these processes occur will allow for potential targeting of specific partner
interaction sites within the cytoplasmic tail to preferentially impede certain signaling
networks that may be activated in pancreatic cancer.
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Figure 3.1: MUC1.CT is Extenstively Phosphorylated
A) Sequence of the 158 MUC1.CT. Extracellular, transmembrane, and cytoplasmic tail
domains are highlighted in each box. Consensus N-glycosylation site and potential
phosphorylation sites(*) are also highlighted. B) 2D gel western blot analysis of
MUC1.CT in normal mouse pancreas and KPC tumor. For each experiment 175 µg of
protein lysate were used. Isoelectric point is mapped below, as well as a prediction of
isoelectric point for each phosphorylation event. Treatment of samples with tyrosine
phosphatase results in shift towards predicted isoelectric point. These studies were
performed on multiple, independent samples. C) Western blot analysis of MUC1.CT
using phosphospecific antibodies against the cytoplasmic tail. Each epitope is
highlighted below the blot with the Red residue indicating the site of phosphorylation.
Western blots were repeated multiple times to optimize antibody concentration and
confirm reproducibility
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Figure 3.2: Different Stimuli Induce Different Phosphorylation Patterns on MUC1
Panc1.MUC1-HA cells were serum starved for 24 hours prior to stimulation with either
100 ng/ml EGF or 10% FBS containing media for 30 minutes. Cells were lysed and
analyzed by 2D gel electrophoresis followed by western blot analysis for MUC1
expression. Each was sample was prepared identically with 175 µg loaded on the gel.
Blots were scanned at the same time to control for exposure. EGF stimulation caused a
specific hyperphosphorylated shift to very low pH range, whereas FBS stimulation
resulted in a wide range of phosphorylation patterns spread out over the entire 3-10 pH
range. The images are representative images of multiple experiments.
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Figure 3.3: N-Glycosylated MUC1 is Present in the Nucleus
A) Western blot analysis of MUC1.CT in normal mouse pancreas with or without
PNGase F treatment. Samples were prepared identically and split prior to treatment to
yield two equal concentrations for the gel. With treatment a shift in molecular weight is
observed corresponding to loss of N-glycosylation. B) Western blot of S2013.Neo and
MIF cytoplasmic and nuclear fractions for expression of MUC1. MUC1 is present in both
the cytoplasmic and nuclear fractions and exists as all 3 species we commonly observe.
GAPDH was used as a loading control for the cytoplasmic fraction C) Western blot
analysis of nuclear MUC1 following treatment with PNGase F. The shift in molecular
weight indicates a loss of N-glycosylation. H2B serves as the loading control. All
western blots were repeated multiple times to ensure reproducibility. For all western
blots 30 µg of lysate was used.
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Figure 3.4: MUC1.CT Processing is not Impacted by TACE Inhibition
Western blot analysis of MUC1 expression in S2013.MIF cells following treatment with
TAPI-2 over 12 or 24 hours. 30 µg of protein lysate was loaded for each sample. No
substantial changes were observed in any of the products detected by CT2. β-actin
serves as a loading control.
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Figure 3.5: Putative In Vitro Self-Cleavage of MUC1.CT
A) General schematic of the chemical processes involved in intein self-cleavage. Initial
steps involve nucleophilic attack typically involving cysteine and serine residues. These
steps are followed by rearrangements that result in excision of the intein and joining of
the two-extein portions. These reactions can be catalyzed in vitro through addition of
reducing agents. B) Multiple preparations of recombinant His-tagged MUC1.CT (158
amino acids) were isolated from C41 or C43 E.coli using Nickel affinity column and
analyzed by western blot analysis under non-reducing or reducing conditions. Nonreducing conditions show potential dimerization of monomeric MUC1, reduction causes
loss of these high molecular weight forms and formation of smaller molecular weight
forms, suggesting a self-cleavage event.
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Figure 3.6: MUC1 Splice Variants are Extensively Phosphorylated
A) Exon map showing the alternative splicing of MUC1/X, MUC1/SV3, and MUC1/Y. All
three of these variants retain the cytoplasmic tail and are detectable using the CT2
antibody. MUC1/Y does not undergo SEA cleavage and thus is larger than MUC1/X.
MUC1/SV3 lacks all of exon 4 and is the smaller than both X and Y B) 2D gel analysis
was performed using HPNE cells transfected with specific MUC1 splice variants. All
gels contained 175 µg of protein lysate. The MUC1 antibody CT2 was used for
detection. The variants did exhibit slightly higher than predicted molecular weight and
the smear of higher weight forms suggests that these variants may be glycosylated.
However, each form did run according to its relative size as compared to the other
variants. These variants all showed significant deviations to the left off the predicted
isoelectric point (*), indicating extensive phosphorylation.
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1. Key Findings
•

Expression of MUC1 drives increased expression and activity of c-Jun

•

MUC1 promotes association of c-Jun and FRA-1, likely in an ERK dependent
manner

•

FRA-1 promotes migration, invasion, and overall tumor growth in pancreatic
cancer cells

•

Expression of FRA-1 is increased in clinical specimens of pancreatic ductal
adenocarcinoma

•

Expression of FRA-1 correlates with expression of pro-EMT genes in a subset of
clinical specimens

•

MUC1 modulates expression of FRA-1:EMT genes
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2. Introduction
Pancreatic ductal adenocarcinoma (PDAC) is a prominent cause of cancer
related deaths worldwide. Despite recent advances in therapeutic treatment, the
prognosis for patients remains relatively unchanged, with a median survival of about 6
months and a 5-year survival of only 6% [1]. Several factors contribute to the poor
outcome of pancreatic cancer, including difficulties in early diagnosis and the propensity
of the cancer to metastasize to distant sites early in progression [1, 276]. As such, there
is a vital need for improved understanding of the mechanisms by which pancreatic
cancer cells disseminate throughout the body and potential ways to specifically target
these metastatic cells. MUC1, a member of the mucin family of glycoproteins that is
commonly overexpressed and aberrantly glycosylated in pancreatic cancer [277] is
known to modulate the invasive and metastatic potential of cancer cells. MUC1 acts by
influencing the balance of adhesive and anti-adhesive properties, and by engaging in
morphogenetic signaling that communicates information about structural and
microenvironmental conditions at the cell surface to the nucleus in a manner that alters
gene expression [20]. MUC1 exists at the cell surface as a heterodimer comprised of a
large N-terminal extracellular mucin domain that is non-covalently associated with a Cterminal domain containing a short extracellular domain, transmembrane region, and a
cytoplasmic tail [19]. The cytoplasmic tail is differentially phosphorylated by different
receptor tyrosine kinases and serine and threonine kinases in response to cytokine
stimulation, physical interactions with counter-receptors, or other factors, and acts as a
relay of signals from the cell surface to the nucleus [19, 20, 26]. In cancer, MUC1
potentiates oncogenic signaling through downstream effectors [26] and acts as a
transcriptional co-regulator in conjunction with transcription factors such as p53, βcatenin, and c-Jun [26, 77, 102]. This wide range of interaction partners allows MUC1 to
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act as a signaling hub, integrating signals from cytokine receptor status, cellular
structure, and other microenviromental conditions to alter cellular behavior. Among
these, are the capacity to influence migration and invasion potential [278-280].
One critical transcription complex impacted by MUC1 is activator protein 1 (AP1), a transcription factor comprised of Jun and Fos proteins that were among the first
oncogenic proteins discovered [125, 173]. The Jun family of proteins includes c-Jun,
JunB, and JunD, and the Fos family consists of c-Fos, FosB, FRA-1, and FRA-2 [126].
Jun and Fos proteins exhibit varying degrees of transforming effects on cells, and the
function of these proteins is dependent on the formation of specific dimers. Jun proteins
can homodimerize or form Jun:Fos heterodimers. Dimers that comprise AP-1
transcription factors can bind to TPA response elements (TRE) within DNA to regulate
transcription, though the DNA elements bound depend in part on the composition of the
dimer [123, 126]. The AP-1 regulated targets, matrix metalloproteases 1 (MMP1) and
connective tissue growth factor (CTGF), are known targets of MUC1’s co-regulatory
activity [77, 100], and we have previously shown that MUC1 over-expression decreases
the apparent binding of c-Jun to the CTGF promoter element [100]. However, the
impact of MUC1 expression on other targets of AP-1 has not been studied and how
MUC1 mediates the displacement of AP-1 from specific promotes remains unknown.
Based on the capacity of different AP-1 dimers to bind unique promoter elements, we
hypothesized that MUC1 may alter the composition of the AP-1 dimer as a result of
integrating oncogenic signaling events to regulate expression of genes associated with
migration and invasion.
In this chapter, we examined how MUC1 modulated AP-1 (c-Jun and FRA-1)
activity and thereby affected the migratory and invasive properties of pancreatic cancer
cells. Our results provide the first evidence that in concert with ERK activation, MUC1
modifies the formation of AP-1 dimers to preferentially favor c-Jun:FRA-1, which in turn
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enhances the migration and invasive potential of pancreatic cancer cells in vitro. We
show that MUC1 acts as a dominant regulator of FRA-1 function at the CTGF promoter
and promotes expression of FRA-1 targets involved in migration and invasion.
Increased expression of FRA-1 mRNA and protein was also observed in clinical PDAC
samples, and a subset of clinical samples exhibited a FRA-1: EMT gene expression
signature. Knockdown of FRA-1 significantly impacted tumor growth in vivo, further
supporting the hypothesis that a novel FRA-1/MUC1 axis contributes to the
aggressiveness of PDAC.

3. Results
MUC1 increases levels of active c-Jun in tumor cells
Previous studies demonstrated that MUC1 affects AP-1 regulation of target
genes in pancreatic cancer cell lines [77, 100]. We initially evaluated the possibility that
this was due in part to the influence of MUC1 on levels of c-Jun in two MUC1overexpressing human pancreatic tumor cell lines, S2013.MIF and Panc1.MUC1, as
compared to their low-expressing counterparts. Analysis of total c-Jun in cytoplasmic
and nuclear fractions showed an increase in total c-Jun within the nucleus of MUC1
overexpressing cells (Fig. 4.1A & B). MUC1 expression also increased c-Jun activation
through phosphorylation at serine 73. Similarly, examination of pancreatic tumor cell
lines derived from tumors of KPC mice that expressed or were null for Muc1 showed a
modest increase in total c-Jun within the nucleus when MUC1 was expressed (Fig.
4.1C). These observations were confirmed in vivo by analysis of normal mouse
pancreas and primary pancreatic tumors derived from Muc1 expressing and Muc1-null
KPC mice, which showed undetectable levels of c-Jun in normal pancreas as compared
to tumor samples, and that c-Jun expression was further enhanced in tumors expressing
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Muc1 (Figure 4.1D). Unlike human tissues, normal mouse pancreas expresses high
levels of MUC1.

MUC1 promotes the formation of c-Jun:FRA-1 dimers
We next investigated the hypothesis that MUC1-mediated increases in c-Jun
levels were due to alterations in dimerization partnerships that are known to stabilize cJun. Previous studies have shown that MUC1 expression leads to displacement of c-Jun
from promoters [77, 100]. The composition of c-Jun heterodimers is known to impact the
DNA binding affinity and specificity [197, 198]. We therefore evaluated dimer
composition by proximity ligation assays to assess the effect of MUC1 on interactions
between c-Jun and a subset of known dimerization partners (c-Fos, FRA-1, and ATF2),
which were chosen based on published roles in DNA binding, transformation, or
metastatic phenotype. Representative images of PLA experiments are shown in Figure
4.2A. Quantification was performed using the Blobfinder program and results are
presented as a representation of mean interactions per cell [281], which were further
subdivided into cytoplasmic and nuclear localization (Figure 4.2B). MUC1
overexpression did not significantly affect nuclear interactions between c-Jun and ATF2
or c-Fos; however, c-Jun:FRA-1 interactions were significantly increased (Fig. 4.2C). As
a secondary validation that MUC1 promoted the association of c-Jun and FRA-1, we
performed co-immunoprecipitation/western blotting assays to detect stable interactions
between FRA-1 and c-Jun. The results showed increased amounts of c-Jun associated
with FRA-1 in cells over-expressing MUC1 (Figure 4.2D) confirming that MUC1
promoted the association of c-Jun and FRA-1.

MUC1, ERK, and FRA-1 regulate the migratory and invasive potential of pancreatic
cancer cells
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Upregulation of FRA-1 is commonly observed in metastatic breast cancer [186188, 282], where it is hypothesized that FRA-1 acts as a driver of invasion and
metastatic spread of cancer cells. We sought to determine if FRA-1 played a similar role
in pancreatic cancer. Given our evidence that FRA-1:c-Jun interactions increased with
MUC1 overexpression, that FRA-1 can be phosphorylated via ERK, and that MUC1 is
known to promote signaling through the ERK pathway [81, 126], we investigated the
effects of MUC1 over-expression on ERK activation. We determined the levels of total
ERK1/2 and phosphorylated ERK1/2 by western blot analysis on subcellular fractions of
S2013.Neo and MIF cells. The results showed increased levels of phosphoERK2 in the
nucleus of MUC1-overexpressing cells (Figure 4.3A). Panc1.MUC1 cells also exhibit
increased ERK2 phosphorylation (Figure 4.4). We confirmed that ERK activation was
responsible for activation of FRA-1 by treating S2013.Neo and MIF cells with the MEK
inhibitor U0126. Western blot analysis indicated that U0126 reduced phosphorylation of
both ERK and FRA-1 (Figure 4.3B).
The results of migration and invasion assays using Boyden chamber inserts
showed that inhibition of ERK signaling by U0126 treatment resulted in approximately
40% reduction of the number of migrating MUC1 expressing cells, while no effect was
observed in S2013.Neo cells (Figure 4.3C), supporting the hypothesis of activation of
FRA-1 enhanced motility in pancreatic cancer cells in concert with MUC1. Similar
results were observed for the invasive potential of S2013.MIF cells, indicating increased
sensitivity to loss of FRA-1 activity (Figure 4.3D). We confirmed the role of FRA-1 in
modulating motility by shRNA knock down studies [confirmed by RT-PCR and western
blot analysis (Figure 4.5A)]. Decreased FRA-1 expression resulted in decreased
migration and invasion. Similar to the effect of ERK inhibition, knockdown of FRA-1
decreased migration and invasion to the greatest degree in cells overexpressing MUC1.
Conversely, overexpression of FRA-1 (Figure 4.5B) greatly increased the migratory and
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invasive properties of S2013 cells, whether or not MUC1 was expressed, though cells
overexpressing MUC1 and FRA-1 showed the highest migratory and invasive activities
(Figure 4.3C and 4.3D). Similarly, overexpression of FRA-1 in Panc1.Neo or
Panc1.MUC1 cells significantly increased both migration and invasion (Figure 4.3E and
4.3F), whereas knockdown decreased these properties. Notably, as for S2013 cells,
these effects were higher in cells expressing higher levels of MUC1. Overexpression of
FRA-1 also altered the morphology of the cells. Increased numbers of elongated cells
with filipodia-like projections were observed in culture (Figure 4.6A-B). Evaluation of
these cells for proliferation revealed that at 48 hours, FRA-1 overexpression did not
impact cellular growth; however, over longer time frames FRA-1 slightly enhanced
proliferation as assessed by methylene blue growth assay [264] (data not shown).

Loss of FRA-1 expression decreases tumor growth and metastases
To evaluate the role of FRA-1 in the development and progression of pancreatic
ductal adenocarcinoma, we performed orthotopic studies evaluating tumor growth of
S2013.Neo and MIF cells with or without knockdown of FRA-1 expression. 150,000
cells were injected into the pancreas of nude mice and tumors allowed to progress for 30
days before mice were sacrificed. Knockdown of FRA-1 expression resulted in
significant reduction of primary site growth as assessed by both tumor weight and tumor
volume in S2013.Neo (Figure 4.7A-B). This effect was enhanced in S2013.MIF cells
(Figure 4.7D-E). Interestingly, one mouse in the S2013.MIF-FRA1 kd group failed to
develop a palpable tumor, though a small tumor was detected by microscopy.
Knockdown of FRA-1 also resulted in a reduction in the development of ascites.
Metastatic spread was assessed by gross analysis of tissues during necropsy
and confirmed by microscopic examination of collected tissues. Knockdown of FRA-1
resulted in a 10-30% reduction in metastases in S2013.Neo, though some sites showed
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no differences, such as liver metastasis. The effects were less pronounced with high
levels of MUC1 expression in S2013.MIF (Figure 4.7C & F).

FRA-1 is upregulated in pancreatic cancer
The role of FRA-1 in pancreatic cancer remains relatively unexplored, though it is
expressed in numerous pancreatic cancer cell lines [194]. We investigated the
possibility that FRA-1 contributes in vivo to pancreatic cancer progression by evaluating
gene expression of FOSL1, which encodes FRA-1, in PDAC samples. Our initial
analysis included evaluation of the GEO database for microarray expression data of
pancreatic ductal adenocarcinoma samples that were compared to normal pancreatic
tissues. Using the data series of GSE16515, consisting of 52 samples (36 tumors and
16 normal samples), we evaluated the gene expression levels of FRA-1 [283, 284].
Analysis of relative expression levels of FOSL1 using the Generalized Estimating
Equation (GEE) [285] revealed significant upregulation (p<0.001) in tumors as compared
to normal samples (Figure 4.8A). To confirm the results were not skewed by a few
highly expressing tumors, we compared the 16 tumors that were matched to samples of
uninvolved pancreas included in this data set. Log2Fold Change was utilized to compare
overexpression between tumor and normal samples. We observed that 15 of 16 samples
showed upregulation of FOSL1, and 8 exhibited a change of greater than 2 fold (Figure
4.8B).
Our in vitro studies suggest FRA-1 expression is important for invasive potential.
To assess whether FRA-1 expression changed during the progression of pancreatic
cancer, we evaluated the data series GSE42952, which includes tumor stage and some
matched primary and metastatic tumors. FOSL1 expression was plotted for each tumor
stage identified within the data set, ignoring absent calls (Figure 4.8C) [284, 286]. For
metastatic sites we differentiated between the identified liver or peritoneal metastatic
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site. Late stage tumors showed a slightly higher trend of FOSL1 expression, particularly
within liver metastases, but the low number of samples prevented us from making
reliable conclusions based solely on these data. As a second evaluation, we performed
immunohistochemistry using tissue microarrays of matched sets of primary and
metastatic tumors derived from the UNMC Rapid Autopsy Program. FRA-1 expression
was examined in primary site tumor, metastatic sites, and normal pancreas from multiple
patients (Figure 4.9). A heatmap was generated based upon the intensity of staining
observed within tumor cells with representative images for scoring presented (Figure
4.8D). Most cancer cells exhibited robust nuclear staining, whereas FRA-1 was absent
in normal pancreas samples; however there were no consistent trends of higher
expression in metastatic samples in this limited analysis. Expression of FRA-1 also
varied in different tumor samples. Thus we conclude that FRA1 is upregulated in some
but not all pancreatic cancers.

FRA-1 overexpressing tumors exhibit a FRA-1:EMT signature
Recently a FRA-1:EMT signature has been proposed for colorectal cancer cells
overexpressing a flagged FRA-1 construct [170]. Eight genes identified as regulated by
FRA-1 were found to represent part of an Epithelial to Mesenchymal Transition (EMT)
associated signature: VIM, FN1, FOSL1, ZEB1, SNAI2, AXL, TGFB2, and SMAD3. We
chose to examine gene expression of 6 of these genes (FN1, ZEB1, SNAI2, AXL,
TGFB2, and SMAD3) in PDAC samples. The GSE16515 PDAC data set was analyzed
for a similar signature. We evaluated paired samples that overexpressed FOSL1 at least
two-fold, which were predicted to exhibit a FRA-1 associated phenotype [283].
Calculation of Log2Fold Change for each paired set of tumor and normal samples for
these targets (Figure 4.10A-F) showed a substantial correlation between FRA-1
expression and upregulation of these EMT signature mRNAs. 5 of the 6 targets (FN1,
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ZEB1, SNAI2, AXL, and SMAD3) were upregulated in at least 60% of the tumors with
high FRA-1 expression; however TGFB2 showed no consistent trend. Tumor samples
5, 8, 11, 13, and 15 were most consistent with the predicted FRA-1 signature, mirroring
the predicted trend 100% of the time for genes other than TGFB2. These results support
the hypothesis that pancreatic cancer exhibits a FRA-1 driven EMT signature, though
only within a subset of cases.
To examine whether protein expression of these genes correlated with FRA-1 in
patient samples, we performed IHC for Slug (SNAI2) and ZEB1 on matched sets from
our rapid autopsy program (Figures 4.11 & 4.12). Slug was observed in most samples,
though it was absent in a FRA-1 negative tumor. ZEB1 was absent in most samples, but
present in a few tumors highly expressing FRA-1. A heatmap representing the IHC
pattern was generated using R (Figure 4.13). These results suggested that even though
there were effects on mRNA levels, there was not a direct correlation between
expression of FRA-1 and the protein products of its target genes Slug and ZEB1 in
clinical samples, demonstrating that factors other than mRNA levels influence steady
state protein levels of these proteins.

MUC1 regulates expression of FRA-1:EMT gene targets
As previous studies have demonstrated the capacity of MUC1 to regulate
expression of MMP1 and CTGF, we sought to examine how the interplay of MUC1 and
FRA-1 impacted expression of these genes[77, 287]. We performed RT-PCR analyses
of our S2013.Neo, S2013.MIF, Panc1.Neo, and Panc1.MUC1 cell lines in conjunction
with FRA-1 overexpression or knockdown to examine expression of MMP1 and CTGF.
Expression of FOSL1 was used as a positive control to confirm overexpression or
knockdown of FRA-1. Results indicated that increased MUC1 expression dramatically
impacts expression of MMP1 and CTGF in S2013 cells. Overexpression or knockdown
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of FRA-1 did not reverse these effects, indicating a dominance of MUC1 effects at these
sites, whereas loss of FRA-1 in S2013.Neo resulted in CTGF expression comparable to
that observed in S2013.MIF (Figure 4.14A). These results were more modest in Panc1
cells and reflect a less robust impact of MUC1 on expression of these targets in this cell
line (Figure 4.14B).
To examine whether MUC1 impacted expression of FRA-1:EMT genes, we
performed additional RT-PCR studies examining expression of SNAI2, ZEB1, TGFB2,
AXL, SMAD3, and FN1. Expression of MUC1 in S2013 cells caused significant
upregulation of many of the FRA-1:EMT genes, including SNAI2, ZEB1, AXL, and FN1.
Loss of FRA-1 caused significant reduction of these genes to levels comparable to the
S2013.Neo cell line. The impact of FRA-1 knockdown in the Neo cell line was relatively
modest on most FRA-1:EMT genes (Figure 4.14C). Once again these effects were less
pronounced in the Panc1 cell lines, though AXL was impacted by MUC1 expression
(Figure 4.14D).

4. Discussion
That MUC1 affects gene expression is well established [80, 89, 103, 288];
however, the mechanism by which MUC1 regulates transcription and affects tumor
progression is not fully understood. MUC1.CT is known to interact with a wide range of
transcription factors including p53, β-catenin, c-Jun, and others [77, 100, 102]. Previous
studies have shown that MUC1 displaces c-Jun from promoters of known target genes;
the data presented here demonstrates this effect is not the result of decreasing the
levels of c-Jun within the cell. Rather, our results indicate that high levels of MUC1 alter
the AP-1 transcriptome in part by increasing steady state levels of c-Jun protein. We
went on to demonstrate that this stabilization of c-Jun results in enhanced association
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with FRA-1 in cells expressing high levels of MUC1, suggesting that MUC1 alters the
stoichiometry of AP1 protein complexes, which in turn modifies transcriptional activity
(Figure 4.15).
We found that MUC1 acts as a dominant regulator of FRA-1 activity that in turn
modulates expression of CTGF and MMP1. Additionally, MUC1 upregulated expression
of several genes associated with FRA-1 mediated EMT. Steady state mRNA levels for
these genes were reduced upon FRA-1 knockdown. Together, these results suggest that
MUC1 serves as a co-activator for FRA-1 at many FRA1-EMT sites, whereas it may
function as a de-repressor of FRA-1 at the CTGF and MMP1 sites. The results were
less apparent in Panc1 cells, which may be attributed to differences in context
dependent constitutive signaling between the S2013 and Panc1 cell lines. Indeed, the
impact of MUC1 on the migration and invasion of Panc1 cells was more modest than the
effects on S2013 cells. Thus, it is not surprising that expression of genes involved in
migration and invasion are not substantially altered in the Panc1 cells.
Consistent with the findings reported here, FRA-1 has been shown to impact
migration, invasion, and metastasis in a number of different cancers [126, 170, 187,
188]. In particular, the role of FRA-1 is well characterized in breast cancer, which also
commonly exhibits MUC1 over-expression and consequent effects on signaling. Similar
to breast cancer, FRA-1 enhances the migratory and invasive capacity of pancreatic
cancer cells. The finding of a cooperative effect between MUC1 and FRA-1 that resulted
in substantial increases in migration and invasion addresses in part the finding that these
factors show differential effects on transcription of different genes. It is likely that one
function of MUC1 is to integrate morphogenetic and oncogenic signals that arise from
cell surface structural conditions, cytokine and growth factor stimulation and steady state
signaling within the cell [19] to help enact programs of transcriptional response to these
composite sets of stimuli from the cellular microenvironment and internal signaling
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apparatus. Programs of cellular activity (e.g. EMT, cell migration, cell division, other
cellular functions) require differential transcriptional responses (up-regulation and downregulation of different sets of genes), and so it is not surprising that an integrator of
signaling such as MUC1 would act as both a co-activator and a co-repressor. For
results examined here, inhibiting ERK activation or knocking down expression of FRA-1
produced similar effects in MUC1 expressing cells, which supports the hypothesis that
MUC1 integrates ERK signaling with morphometric signals related to motility and
invasion. Furthermore, we demonstrated that MUC1 enhanced steady state ERK
activation in pancreatic cancer cells, further supporting the link between ERK activation
and the functional activity of MUC1 and FRA-1. Previous studies have also
demonstrated the capacity for MUC1 to promote ERK mediated signaling, however,
these studies did not evaluate the impact on downstream transcriptional machinery[81,
86]. These results serve as the first reported evidence of cooperative signaling between
MUC1 and FRA-1. This finding could have important implications not only in pancreatic
cancer, but also in other cancers with aberrant expression of cell surface mucin proteins
that engage in signal transduction [19].
Despite the known synergy between AP-1 and oncogenic Ras, few studies have
examined the expression of AP-1 proteins in pancreatic cancer, which contains K-Ras
mutations in a vast majority of cases [128, 287]. Our analysis of data from the GEO
database suggested that FRA-1 is transcriptionally upregulated during the progression
from normal to cancerous pancreatic tissue and FRA-1 mRNA may also be upregulated
as the tumor progresses to metastasis. Immunohistochemistry supported these
analyses in part, as pancreatic tumors exhibited robust nuclear staining for FRA-1 and
expression was retained in liver metastases. FRA-1 staining was absent in samples of
normal pancreas. A set of FRA-1 target genes identified in studies of colorectal cancer
studies was confirmed here for pancreatic cancer. Recently, it has been proposed that
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pancreatic cancer consists of 4 distinct subtypes based on genomic analyses [18].
Interestingly, the squamous subtype of pancreatic cancer proposed exhibits high
expression of FOSL1, TGFB2, SNAI2, and FN1; all genes we’ve studied within the
FRA1:EMT phenotype. This suggests that our proposed FRA1:EMT subset and the
squamous subtype of pancreatic cancer may be the same group. Immunohistochemistry
analysis of clinical samples obtained at autopsy provided additional support for the
hypothesis that FRA-1 was associated with expression of these genes; however, it was
also apparent that the levels of expression of proteins encoded by the target genes are
influenced by other factors. Future studies in which the tumors can be stratified
according to the recently identified subtypes may allow for easier correlations to be
drawn. Additionally, the dependence of FRA-1 activity on ERK activation suggests that
tumors (such as pancreatic cancer) bearing activating mutations with the Ras-Raf-MEKERK cascade are likely to exhibit FRA-1 based effects.
Our results support the hypothesis that FRA-1 contributes significantly to
metastasis of pancreatic cancer, at least within a subset of cases and also plays an
important role in overall tumor progression. Reduction of FRA-1 expression by as little
as 2-3 fold produced significant reductions in primary site tumor growth in an orthotopic
model of pancreatic cancer. Metastases were also reduced, though they were not
completely inhibited. Recent studies have highlighted a potential role for FRA-1 in
anchorage independent growth [289]. Other studies have highlighted the importance of
FRA-1 in promoting YAP driven oncogenesis [290], which is important in the progression
of pancreatic cancer. These results suggest FRA-1 may be a viable target to inhibit the
growth and dissemination of pancreatic cancer cells. To date no specific inhibitors to
FRA-1 have been characterized, though various inhibitors such as bromodomain
inhibitors impact FRA-1 expression [289, 291]. As FRA-1 exhibited a number of effects
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independent of MUC1, future studies focused on FRA-1 alone may provide further
insight into the possibility of targeting FRA-1.
In conclusion, our work presents the first evidence that MUC1 can function by
altering the composition of AP-1 protein complexes involved in transcriptional regulation.
This function explains some of the effects of MUC1 on the expression of genes involved
in migration and invasion, particularly those that are known targets of FRA-1. We further
highlight the functional role of these changes as drivers of metastatic and invasive
potential in pancreatic cancer cells. Given that 90% of pancreatic cancer patients exhibit
metastatic spread at diagnosis, the mechanisms behind the early dissemination of
pancreatic cancer cells need further study [1]. Whereas the mechanism identified in this
manuscript identifies aspects of the biology of MUC1 in modulating transcriptional
effects, our in vivo and in vitro studies suggest FRA-1 can independently contribute to
effects on tumor progression. Additional study of FRA-1 in pancreatic tumor specimens
is warranted, as is further study of the specific and redundant functions of c-Jun
heterodimers in pancreatic cancer. Future studies should also be undertaken to identify
potential therapeutic targets of specific AP-1 heterodimers.
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Figure 4.1: MUC1 Increases Expression of c-Jun Protein
A-B) Cytoplasmic and nuclear fractions of S2013.Neo and MIF cells were western
blotted for c-Jun, phosphoJun, and MUC1; H2B blotting was evaluated for normalization
and purity assessment. C) Cytoplasmic and nuclear fractions of cell lines established
from the tumors of KPC mice that either expressed (MUC1 WT) or lacked MUC1 (MUC1
KO) were blotted for c-Jun and MUC1 expression with H2B used for normalization and
purity assessment. D) Whole cell lysates prepared from normal mouse pancreas and
tumors derived from KPC mice (either MUC1 WT or KO) and were blotted for expression
of c-Jun and MUC1 with β-actin as a loading control.
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Figure 4.2: MUC1 Enhances the Interaction of c-Jun and FRA-1 in Pancreatic
Cancer Cells
A) Proximity ligation assay examining interactions of c-Jun with the proteins ATF2, cFos, and FRA-1 in S2013.Neo and MIF cells. Experiments were performed in four
independent assays; with multiple fields were quantified for each experiment.
Representative fields are shown and red dots indicate protein-protein interaction. B)
Quantification of interactions between c-Jun and associated partners. Quantification
was performed using the Blobfinder program and results presented as the average
number of interactions per cell±SEM. Significance was assessed using Student’s t-test
p<0.05 was considered significant. C) Comparison of the nuclear interactions of c-Jun
and the associated proteins in S2013.Neo and MIF cells. Results represent the
percentage of nuclear interactions/ total interactions±SEM. Significance was assessed
with Student’s t-test D) FRA-1 was immunoprecipitated from Neo and MUC1
overexpressing cell lines. The association of FRA-1 and c-Jun was then assessed by
western blot analysis of co-immunoprecipitated c-Jun. Levels of c-Jun were normalized
based upon amount of FRA-1 pulled down and compared between Neo and MUC1 cell
lines. Western blot analysis of input confirms MUC1 expression.
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Figure 4.3: ERK Activity and FRA-1 Drive Invasion and Migration of Pancreatic
Cancer Cells
A) Cytoplasmic and nuclear fractions were isolated from S2013.Neo and MIF cells and
western blot analysis performed for total ERK1/2, phosphoERK1/2, and MUC1. H2B
was used for normalization and purity assessment. Densitometry values are shown
below the figures. B) S2013.Neo and MIF cells were serum starved for 24 hours,
treated with the MEK inhibitor U0126 or DMSO control for 2 hours, then stimulated with
10% FBS containing media to induce ERK activation. Western blots for phosphoERK1/2
and phosphoFRA-1. C-F) Effects of inhibiting ERK Signaling (U0126), knocking down
FRA1 mRNA, or overexpressing FRA1 mRNA on Migration (C & E) and Invasion (D & F)
in the context of low or high expression of MUC1.
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Figure 4.4: ERK Activity is Increased in Panc1.MUC1 Cells
A) Western blot analysis evaluating the expression of total ERK1/2 and phosphoERK1/2
in Panc1 cells. Relative amounts were determined by densitometry using H2B as a
loading control. Calculations were performed for each localization and are for ERK2
only. Results show increased levels of phosphoERK with MUC1 expression.
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Figure 4.5: Validation of FRA-1 Knockdown and Overexpression Cell Lines
A) Characterization of FRA-1 knockdown cell lines. FRA-1 experession was knocked
down by shRNA and expression of FRA-1 was assessed by both western blot analysis
and RT-PCR. Reduction in FRA-1 expression was similar between the Neo and MUC1
expressing counterparts. B) Characterization of FRA-1 levels following stable
overexpression of HA-tagged FRA-1 construct. Lysates were probed for FRA-1
expression using an anti-HA antibody and MUC1. Actin served as a loading control.
Both the Panc1 and S2013 cell lines express similar levels of FRA-1 independent of
MUC1 expression allowing for comparisons across cell lines.
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Figure 4.6: FRA-1 Expression Alters Cellular Morphology
Images of cancer cells with and without FRA-1 overexpression were taken using an
EVOS digital microscope. Cells were than examined for changes in cellular morphology.
Both Panc1 (A) and S2013 cells (B) exhibit increased numbers of cells with cellular
projections when FRA-1 was overexpressed (indicated by arrows).
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Figure 4.7: Knockdown of FRA-1 Decreases Tumor Growth and Metastasis
A-B) Tumor weight and Tumor volume were plotted for mice injected with S2013.Neo
(n=12) or S2013.Neo-FRA1 kd (n=12) cells. The mean was calculated ± SD.
Knockdown of FRA-1 resulted in significant reduction of both weight and volume
(Bonferroni adjusted p-values following ANOVA and Bonferroni method for multiple
comparisons). C) Presence of ascites or metastasis was assessed for each individual
mouse and the fraction of total mice for each condition was calculated. D-E) Tumor
weight and volume plotted for mice injected with S2013.MIF (n=13) or S2013.MIF-FRA1
kd (n=13) cells. The mean was calculated ± SD (Bonferroni adjusted p-values following
ANOVA and Bonferroni method for multiple comparisons). F) Presence of ascites or
metastasis was assessed and presented for each individual mouse.
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Figure 4.8: FOSL1 is Overexpressed in Pancreatic Ductal Adenocarcinoma
Samples
A) Gene expression data from the NCBI GEO dataset GSE16515 was analyzed for
expression of FOSL1 (FRA1) using microarray expression values. Expression values
from tumor and normal samples are presented. Statistical comparison of the groups
was performed using the Generalized Estimating Equation (GEE) to account for the
paired tumor and normal samples. Analysis revealed a significant increase in FOSL1
expression in the tumor group (p<0.001) as compared to normal. B) To confirm tumor
samples upregulated FOSL1 16 paired tumor and normal samples were compared. The
log2Fold Change in gene expression for tumor/normal was calculated and plotted. 15 of
16 samples show upregulation in the tumor. 8 of 16 showed an upregulation greater
then 2 fold (log2Fold Change >1) C) Gene expression data for staged pancreatic tumor
specimens was mined using the NCBI GEO dataset GSE42952. The expression of
FOSL1 was plotted for each specified staging with absent calls ignored. D)
Immunohistochemistry was performed to evaluate the protein expression of FRA-1 in
pancreatic cancer. A heatmap representing relative staining for FRA-1 was generated
using R. Scoring was based upon intensity of stain observed only within tumor cells.
Representative images for the scoring are presented below the heat map.
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Figure 4.9: Analysis of FRA-1 Expression in PDAC Samples
Tissue microarrays were stained for expression of FRA-1. Samples were collected from
the UNMC Rapid Autopsy Program. Each number represents an individual patient.
Primary and metastatic sites were stained and compared to normal pancreas.
Metastatic sites were collected from the liver unless otherwise indicated.
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Figure 4.10: Pancreatic Cancer Samples Exhibit Similar FRA1:EMT Signature as
Colorectal Cancer Cells
A-F) Gene expression data from the NCBI GEO dataset GSE16515 for 6 FRA1:EMT
signature genes (FN1, ZEB1, SNAI2, AXL, TGFB2, SMAD3) were plotted. For genes
with multiple probes the average of all probes was used. Only tumors showing >2-fold
upregulation of FRA-1 were used for this analysis.
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Figure 4.11: Analysis of Slug Expression in PDAC
Tissue microarrays were stained for expression of Slug. Samples were collected from
the UNMC Rapid Autopsy Program. Each number represents an individual patient.
Primary and metastatic sites were stained and compared to normal pancreas.
Metastatic sites were collected from the liver unless otherwise indicated.
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Figure 4.12: Analysis of ZEB1 Expression in PDAC Samples
Tissue microarrays were stained for expression of ZEB1. Samples were collected from
the UNMC Rapid Autopsy Program. Each number represents an individual patient.
Primary and metastatic sites were stained and compared to normal pancreas.
Metastatic sites were collected from the liver unless otherwise indicated.
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Figure 4.13: Heatmap of Immunohistochemistry Studies
Heatmaps were generated based upon staining of FRA-1, Slug, and ZEB1 in
pancreatic cancer samples. Scoring was based upon relative intensity of staining and
each TMA was scored independently to avoid bias based upon antibody differences.
Scoring was restricted to tumor cells.
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Figure 4.14: MUC1 Regulates Specific AP-1 and FRA-1 Targets
A-B) RT-PCR studies were performed to examine the impact of FRA-1 on the MUC1
regulated genes MMP1 and CTGF. FOSL1 expression was measured to confirm
overexpression or knockdown of FRA-1. Results were analyzed by 2-way ANOVA and
p-values represent comparison of FRA-1 overexpression and knockdown lines to
parental unless otherwise indicated by lines. MUC1 expression caused significant
alterations to expression of MMP1 and CTGF. Alteration of FRA-1 expression had no
impact on expression in S2013.MIF, but significantly altered expression of these genes
in S2013.Neo C-D) Additional RT-PCR studies were performed to examine the impact
of MUC1 and FRA-1 on expression of putative FRA1:EMT genes. Results were
analyzed by 2-way ANOVA for multiple comparisons and p-values indicate significant
differences between parental and FRA-1 knockdown cell lines unless otherwise
indicated by lines. In S2013 cells (C) MUC1 caused significant increases in expression
of these genes. Loss of FRA-1 abrogated this effect and restored expression to levels
similar to S2013.Neo cells. Similar effects were observed for the regulation of AXL in
Panc1 cells (D).
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Figure 4.15: MUC1 and ERK Cooperate to Drive Association of c-Jun and FRA-1
Schematic representation of our proposed mechanism in MUC1 expressing pancreatic
cancer cells. Phosphorylation of the MUC1 cytoplasmic tail drives downstream
activation of ERK, likely involving the association of MUC1 with receptor tyrosine
kinases. Increased ERK activity results in phosphorylation of FRA-1 and promotes
dimerization with c-Jun. The transcriptional complex is then stabilized and allows for
expression of genes involved in migration, invasion, and overall tumor progression.
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Chapter V: FRA-1 Knockdown Confers Additive
Benefits to BET Inhibition
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1. Key Findings
•

The impact of BET inhibition on the expression of FRA-1 is variable and likely
depends on multiple factors

•

Overexpression of FRA-1 does not protect cells from growth inhibition with BETi

•

Knockdown of FRA-1 confers additive effects on growth inhibition with BETi

•

Knockdown of FRA-1 does not synergize with G1/G0 arrest induced by BETi

•

Knockdown of FRA-1 results in decreased expression of pro-growth genes and
increased expression of cell death/cytostatic genes
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2. Introduction
Fos-related antigen 1 (FRA-1) is a member of the Fos family of proteins [126],
which together with the Jun family of proteins, comprise the dimeric transcription factor
AP-1 [121]. Initial discovery of the viral oncoproteins v-Jun and v-Fos highlighted the
activity of AP-1 in cancer and has led to extensive exploration of this pathway for
targeted therapy in cancer [121, 292]. The combinatorial diversity of AP-1 that arises
from its capacity to form 18 potential dimeric combinations has led to the demonstration
that AP-1 imparts a wide range of effects, including promotion of cellular growth,
apoptosis, and invasive behavior [121]. These effects are dependent on the composition
of the dimer and are often cell type dependent [121, 165, 198]. FRA-1 has been
identified as a significant driver of invasion and metastasis in breast cancer and
colorectal cancer, however, the impact of FRA-1 on pancreatic cancer remains relatively
unexplored [170, 186, 188, 189].
Pancreatic cancer remains one of the most difficult cancers to treat, with a 5-year
survival rate hovering around 6-7% [1]. Current therapies are largely ineffective and as
a result, there is a vital need to identify novel targets. Recently, we found that FRA-1
expression is increased in a significant fraction of pancreatic ductal adenocarcinoma
(PDAC) samples [169]. Enhanced expression of FRA-1 in pancreatic cancer cells
increased migratory and invasive properties, similar to effects observed in breast cancer
cells. Knockdown of FRA-1 diminished these properties and resulted in diminished
tumor growth and metastasis in vivo. Additional studies have supported a role for FRA-1
in the three-dimensional growth of pancreatic cancer cells in collagen [289]. These
studies suggest that FRA-1 may be a potential therapeutic target in pancreatic cancer.
While there are no current therapies directed against FRA-1, treatment of cells
with inhibitors of bromodomain and extracellular terminal (BET) proteins has shown a
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propensity to decrease expression of FRA-1 and c-Myc [289, 291]. BET expression is
deregulated in a host of cancers and there are currently several clinical trials in progress
examining the efficacy of BET inhibition (BETi). In pancreatic cancer, BETi has shown
the ability to inhibit growth both in vitro and in patient-derived xenografts [293]. Despite
potential effects on FRA-1, most studies of BETi have focused on its effects with c-Myc
[291, 294-296]. One study in lung cancer showed that overexpression of FRA-1 failed to
protect cells from BETi [297]. Our previous results implicating FRA1 in pancreatic
cancer [169] led us to examine how expression of FRA-1 impacted the efficacy of BETi
on pancreatic cancer, and whether dual inhibition of FRA-1 and BET proteins would
result in synergistic decreases in tumor growth. Furthermore, we attempted to confirm
that BET inhibition caused decreased expression of FRA-1.
We found that treatment of pancreatic cancer cell lines with the BET inhibitors
JQ1 and OTX015 failed to consistently decrease expression of FRA-1 in 2-dimensional
growth. Similar to studies in lung cancer, overexpression of FRA-1 did not protect cells
from BETi. However, knockdown of FRA-1 in conjunction with BETi resulted in an
additive decrease in cellular growth, apparently through independent molecular
mechanisms of action. We observed no cooperative effects on cell cycle arrest in cells
treated with BETi and FRA-1 knockdown; however, RNA-seq analysis of FRA-1
knockdown cells revealed significant alterations in cell growth and survival pathways,
suggesting that loss of FRA-1 decreases overall cellular viability. Our results suggest
that targeting of FRA-1 is useful and may increase the therapeutic effect of BETi.

3. Results
BET Inhibition Exhibits Variable Impact on FRA-1 Expression
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Previous studies have shown the treatment of cells with BET inhibitors commonly
results in decreased expression of FRA-1 [289, 291, 298]. To determine if JQ1 or
OTX015 treatment downregulated FRA-1 in pancreatic cancer cell lines, we treated
Colo357, AsPC1, Panc1, and S2013 cell lines with increasing concentrations of either
JQ-1 or OTX015 (50nM to 500nM). Cells were grown as a monolayer and treated for 48
hours before lysis. Western blot analysis of FRA-1 expression showed mixed responses
to BET inhibition. Both Colo357 (Figure 5.1A) and AsPC1 (Figure 5.1C) exhibited no
decrease in expression of FRA-1 in response to either JQ1 or OTX015. Interestingly,
AsPC1 showed increased expression of FRA-1 as the dose of BET inhibitor was
increased. Panc1 (Figure 5.1B) and S2013 (Figure 5.1D) cells showed modest
decreases in the expression of FRA-1 with higher doses of OTX015, though no
decrease of expression was observed with JQ-1. Thus, we conclude that BETi alone
does not consistently modulate expression of FRA-1 in pancreatic cancer cells.
To evaluate the role of FRA-1 expression on the efficacy of BET inhibitors, we
generated both FRA-1 knockdown and FRA-1 overexpression cell lines using the S2013
and Panc1 pancreatic cancer cell lines (Figure 5.1E and 5.1F). Expression of FRA-1
was assessed by both western blot analysis and RT-PCR analyses to confirm that FRA1 was appropriately knocked-down or overexpressed.

Knockdown of FRA-1 Expression Confers Additive Impacts on Cell Growth with
BET Inhibition
Previous studies examining the mechanisms of BET inhibition have focused
primarily on the role of c-Myc on growth. Given that recent studies by our lab and others
have demonstrated that FRA-1 influences pancreatic cancer cell growth both in vitro and
in vivo, we sought to examine whether knockdown of FRA-1 expression would cooperate
with, or inhibit effects of BET inhibition. Parental, FRA-1 overexpressing, and FRA-1
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knockdown cell lines were treated with increasing doses of JQ1, OTX015, or a DMSO
vehicle control. Methylene Blue assays were performed to assess cellular proliferation
over time.
We found that effects of BET inhibition on cell proliferation were not affected
synergistically by FRA-1 overexpression or knock-down in both S2013 (Figure 5.2A-C
and Figure 5.3A-C) and Panc1 (Figure 5.4A-C and Figure 5.5A-C) cells. This shows that
FRA-1 does not protect cells from BET inhibition. Nonetheless, significant inhibition of
growth was observed in most cell lines at 250nM of either JQ1 or OTX015 after 96
hours, and loss of FRA-1 expression significantly decreased growth independent of BET
inhibition for both cell lines in an additive manner. As a result, the combination of FRA-1
knockdown and BET inhibition was significantly better then BET inhibition alone (Figures
5.2-5.5). This was true for both S2013 and Panc1 cells at virtually every dose of BET
inhibitor, though 1 µM OTX015 showed no significant difference in Panc1 cells with
knockdown of FRA-1 (Figure 5H).

Loss of FRA-1 Does Not Synergize with BETi mediated G1 Arrest
As loss of FRA-1 alone is sufficient to decrease cellular growth, we sought to
examine whether the mechanism was independent or synergistic with BETi. Previous
studies of FRA-1 have shown that loss of FRA-1 can result in alterations in cyclin
expression [299-301]. This in turn leads to slower progression through the cell cycle and
decreased cellular proliferation. To test whether FRA-1 caused aberrations in cell cycle
progression, we performed cell cycle analysis on parental and FRA-1 knockdown lines in
the presence or absence of BET inhibition. For these studies, the 500 nM concentration
was chosen based on results showing significant differences in growth between the
parental and FRA-1 knockdown cell lines. BET inhibition caused accumulation of cells in
G1, consistent with the literature [294, 302]. Loss of FRA-1 resulted in accumulation in
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G2/M in Panc1 cells and accumulation in S phase in S2013 cells, suggesting an affect
on cell cycle progression; however, we did not observe synergistic accumulation of cells
in G1/G0 (Figure 5.6A-B).
To test whether FRA-1 expression influenced expression of cyclins, we
performed western blot analysis of lysates from 96-hour treatment time points. Western
blots for Cyclin A and Cyclin D showed that FRA-1 loss promoted decreased expression
in response to BET inhibition in Panc1 cells (Figure 5.6A). However, these effects were
not observed in S2013 cells, suggesting that other factors are involved in decreasing
cellular growth (Figure 5.6B).

Loss of FRA-1 Results in Decreased Cellular Fitness
We performed RNA-seq analysis of the S2013.Neo and S2013.plKO FRA1 cell
lines to identify mechanisms that may explain the decreased cellular proliferation
observed in FRA-1 knockdown cells. Differences in gene expression between the cell
lines were analyzed using QIAGEN’s Ingenuity® Pathway Analysis to identify cellular
pathways that were altered by decreased FRA-1 expression [265]. Heatmaps generated
using QIAGEN’s Ingenuity® Pathway Analysis demonstrate the increased expression of
cell death genes (Figure 5.6C) and decreased expression of proliferative genes (Figure
5.6D), suggesting that loss of FRA-1 may diminish cellular viability. Additionally,
pathways associated with cellular movement and motility were significantly impacted,
which is consistent with the known role for FRA-1 in the migration and invasion of cells
(Figure 5.6E).
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4. Discussion
Bromodomain inhibitors have been studied recently as potential therapeutics for
a wide range of cancers [303-305]. Many of the currently available inhibitors elicit
cytostatic effects on tumor growth, rather than cytotoxic effects [306, 307]. As such, a
priority is identifying potential targets that can synergize with BET inhibitors, or in
combination enhance cytotoxicity. Previous studies have identified FRA-1 as a factor
commonly impacted by BET inhibition [289, 291, 298]. In the studies reported here, we
sought to examine whether targeting FRA-1 would synergize with the BET inhibitors JQ1
and OTX015. Whereas previous studies in breast cancer cell lines found that JQ1
treatment resulted in decreased expression of FRA-1, we found no consistent impact of
BET inhibition on FRA-1 expression in pancreatic cancer. BET inhibition is known to
have variable effects with known targets such as Myc, the most characterized target
[293]. Interestingly, FRA-1 has been shown to control expression of several known Myc
targets, and in some instances FRA-1 affects expression patterns for genes that may
compensate for loss or lack of Myc expression [299]. This may explain in part the
context dependent effects of BET inhibitors.
Cells with reduced FRA-1 activity through knockdown or treatment with BET
inhibitors exhibited a significant reduction in growth as compared to parental lines.
However, this effect appeared to be additive, as loss of FRA-1 expression alone reduced
cellular growth, albeit to a lesser extent. Our finding that overexpression of FRA-1 failed
to protect pancreatic cancer cells from the growth inhibitory effects of BET inhibitors
provided additional evidence that BET inhibitors function independently of FRA-1. This
is consistent with results reported in lung cancer [297]. BET inhibition is reported to
induce G1/G0 arrest, which we also observed [306, 307]. Knockdown of FRA-1 failed to
enhance the arrest induced by either JQ1 or OTX015, further suggesting that oncogenic
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mechanisms of FRA-1 activity can be independent of BETi. As well, western blots
examining cyclin levels failed to identify a consistent mechanism of growth arrest. For
Panc1 cells, loss of FRA-1 induced a cooperative reduction of Cyclin A and Cyclin D1
expression in response to BET inhibition, however, these effects were not observed in
S2013 cells, suggesting that the growth inhibitory effects of knocking down FRA-1 are
not due to effects on these cyclins.
RNA-seq analysis of the S2013 cell lines suggested that the additive effects of
FRA-1 knockdown and BET inhibition resulted from reduced expression of pro-growth
genes and consequent decreases in cellular proliferation. Previous studies in triple
negative breast cancer demonstrated that FRA-1 enhanced cellular growth and
expression of pro-growth genes [185]; however, this has not been previously reported for
pancreatic cancer. Interestingly, expression of FRA-1 has been shown to occur in a
recently identified putative subtype of pancreatic cancer [18]. Taken together, these
results suggest that FRA-1 may be a viable target in a range of cancers and that
inhibiting AP-1 complexes may be additive to effects of BET inhibitors.

Unfortunately,

targeting other AP-1 complexes has proven extremely difficult in the clinical setting [308].
Recently a selective AP-1 inhibitor (T-5224) demonstrated efficacy in a few preclinical
models of cancer [309]. Future studies examining the efficacy of this drug in pancreatic
cancer may provide insight into the utility of broadly targeting AP-1.
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Figure 5.1: FRA-1 Exhibits Variable Responses to BET Inhibition
A) Colo357, B) Panc1, C) AsPC1, and D) S2013 cells were treated with increasing
doses of the BET inhibitors OTX015 or JQ1 and cell lysates were evaluated for the
impact on expression of FRA-1. β-actin was used as a loading control. Western blots
were repeated three times to ensure reproducibility. E) FRA-1 knockdown cell lines
were evaluated for FRA-1 expression by western blot analysis and RT-PCR analysis.
Overall gene expression was normalized to 18s rRNA for RT-PCR analysis. Both Panc1
and S2013 cell lines showed knockdown of FRA-1 expression. F) FRA-1
overexpression cell lines were generated in Panc1 and S2013 cells. Expression of HA
tagged FRA-1 was confirmed by western blot analysis for the HA-tag. Increased
expression of FRA-1 was also confirmed by RT-PCR analysis after normalizing to 18s
rRNA.
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Figure 5.2: JQ1 Treatment Results in Additive Decreases in Cell Growth with FRA1 Knockdown in S2013 Cells
A) S2013 parental cells, B) HA-FRA1, and C) FRA-1 knockdown cells were treated with
different concentrations of JQ1 or DMSO control. Cellular growth was measured by
absorbance at 650 nm with methylene blue assay. Absorbance was plotted over time to
generate growth curves and statistical analyses were performed using 2-way ANOVA
comparing to the control (*p<.05, **p<.01, ***p<0.001). Absorbance values represent
average of 6 wells for each cell line to control for variability in cell plating and growth due
to plate position. D-H) The growth curves for the parental, HA-FRA1, and FRA-1
knockdown lines were compared at each individual concentration. Differences between
the treated parental lines and the FRA-1 knockdown line were assessed using 2-way
ANOVA for each time point (*p<.05, **p<.01, ***p<0.001). Each assay was performed
multiple times to ensure reproducibility.
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Figure 5.3: OTX015 Treatment Results in Additive Decreases in Cell Growth with
FRA-1 Knockdown in S2013 Cells
A) S2013 parental cells, B) HA-FRA1, and C) FRA-1 knockdown cells were treated with
different concentrations of OTX015 or DMSO control. Cellular growth was measured by
absorbance at 650 nm with methylene blue assay. Absorbance was plotted over time to
generate growth curves and statistical analyses were performed using 2-way ANOVA
comparing to the control (*p<.05, **p<.01, ***p<0.001). Absorbance values represent
average of 6 wells for each cell line to control for variability in cell plating and growth due
to plate position. D-H) The growth curves for the parental, HA-FRA1, and FRA-1
knockdown lines were compared at each individual concentration. Differences between
the treated parental lines and the FRA-1 knockdown line were assessed using 2-way
ANOVA for each time point (*p<.05, **p<.01, ***p<0.001). Each assay was performed
multiple times to ensure reproducibility.
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Figure 5.4: JQ1 Treatment Results in Additive Decreases in Cell Growth with FRA1 Knockdown in Panc1 Cells
A) Panc1 parental cells, B) HA-FRA1, and C) FRA-1 knockdown cells were treated with
different concentrations of JQ1 or DMSO control. Cellular growth was measured by
absorbance at 650 nm with methylene blue assay. Absorbance was plotted over time to
generate growth curves and statistical analyses were performed using 2-way ANOVA
comparing to the control (*p<.05, **p<.01, ***p<0.001). Absorbance values represent
average of 6 wells for each cell line to control for variability in cell plating and growth due
to plate position. D-H) The growth curves for parental, HA-FRA1, and FRA-1
knockdown lines were compared at each individual concentration. Differences between
the treated parental lines and the FRA-1 knockdown line were assessed using 2-way
ANOVA for each time point (*p<.05, **p<.01, ***p<0.001). Each assay was performed
multiple times to ensure reproducibility.
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Figure 5.5: OTX015 Treatment Results in Additive Decreases in Cell Growth with
FRA-1 Knockdown in Panc1 Cells
A) Panc1 parental cells, B) HA-FRA1, and C) FRA-1 knockdown cells were treated with
different concentrations of OTX015 or DMSO control. Cellular growth was measured by
absorbance at 650 nm with methylene blue assay. Absorbance was plotted over time to
generate growth curves and statistical analyses were performed using 2-way ANOVA
comparing to the control (*p<.05, **p<.01, ***p<0.001). Absorbance values represent
average of 6 wells for each cell line to control for variability in cell plating and growth due
to plate position. D-H) The growth curves for the parental, HA-FRA1, and FRA-1
knockdown lines were compared at each individual concentration. Differences between
the treated parental lines and the FRA-1 knockdown line were assessed using 2-way
ANOVA for each time point (*p<.05, **p<.01, ***p<0.001). Each assay was performed
multiple times to ensure reproducibility.
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Figure 5.6: Loss of FRA-1 Decreases Cellular Fitness but Fails to Synergize with
BET Inhibition
A) Cell cycle analysis of Panc1 or B) S2013 cells with or without FRA-1 knockdown at
selected time points following treatment with BET inhibitors. The percentage of cells
observed within each phase is presented for each time point. Additionally, western blot
analysis was performed to examine the impact of FRA-1 expression and BET inhibition
on the expression of Cyclin A2 and Cyclin D1. β-actin served as a loading control. C)
Heatmap generated from Ingenuity® Pathway analysis demonstrating increased
expression of genes involved in cell death or D) cellular proliferation. Shading is based
upon differential Z-score. E) List of significantly altered pathways between S2013.Neo
and S2013.plKO FRA-1 cell lines identified using QIAGEN’s Ingenuity® Pathway
Analysis. P-values are calculated based on the odds of finding x number of genes
differentially regulated within the same network.

Figure 5.6
A.

Panc1

Percentage of Cells

100

Panc1.Neo

80
60

Panc1.plKO FRA1

OTX DMSO JQ1

OTX
IB: CyclinD1
IB: CyclinA2

20

IB: β-Actin

0

–

+

–

+

–

JQ1
48 hr

Percentage of Cells

JQ1

40

FRA-1 kd

B.

DMSO

G2/M
S
G1

+

OTX
48 hr

–

+

–

JQ1
96 hr

+

OTX
96 hr

S2013
100

S2013.Neo

80

DMSO

G2/M
S
G1

60

JQ1

S2013.plKO FRA1

OTX DMSO JQ1

OTX
IB: CyclinD1

40

IB: CyclinA2

20

FRA-1 kd

0

IB: β-Actin
–

+

–

+

JQ1
48 hr

–

+

OTX
48 hr

–

+

–

JQ1
96 hr

+

OTX
96 hr

C.

D.
Cell Death and Survival
cell death

Cellular Growth and Proliferation
cell proliferation

cell viability

apoptosis

necrosis

proliferation

colony formation

survival

cytostasis
anoikis

<-2.018

E.

z-score

>2.063

Name

<-2.018

p-value

Cell Death and Survival

1.29E-03 - 3.44E-35

Cellular Movement

1.54E-03 - 3.18E-31

Cellular Development

1.43E-03 - 6.63E-28

Cellular Growth and Proliferation

1.43E-03 - 6.63E-28

Cellular Assembly and Organization

1.29E-03 - 1.72E-19

z-score

>2.063

167

Chapter VI: Impact of p53 Mutation Status on the
Interaction with MUC1 and Potential Gain of Function
Effects
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1. Key Findings
•

MUC1 preferentially interacts with the R273H hotspot mutant of p53, as
compared to wildtype or R175H p53

•

Expression of R273H results in increased expression of CTGF, but wildtype and
R175H p53 are unable to induce CTGF

•

Expression of p53 under steady state conditions has no impact on the cellular
growth of Colo357 cells

•

Irradiation of wildtype p53 expressing cells causes growth arrest quicker than
mutant p53 expressing cells

•

Irradiation induces phosphorylation of wildtype p53 and induction of PUMA, but
does not result in phosphorylation of mutant p53

•

UV damage induces phosphorylation of wildtype and mutant p53, but this effect
is variable depending on the mutation
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2. Introduction
The tumor suppressor p53 is mutated in approximately 50-75% of pancreatic
ductal adenocarcinoma cases [310]. The majority of p53 mutations occur within the
DNA binding domain of p53 resulting in disruptions to normal DNA binding [311]. As a
result, therapeutic intervention to restore wildtype p53 function has been extensively
studied [312]. While it was initially postulated that these mutations resulted in loss of
p53 function, recent studies have indicated that p53 mutants retain variable DNA binding
capacity and may exhibit gain-of-function effects [243, 313-317]. Indeed, in the KPC
pancreatic cancer mouse model, loss of p53 tumors exhibit a distinct phenotype from
tumors arising from mutant p53 [15]. Other studies have also demonstrated that a p53
null allele is not equivalent to a mutant allele, further supporting the potential for gain-offunction effects [239].
The transmembrane glycoprotein MUC1 has been shown to interact with p53
resulting in alterations to downstream transcriptional targets and changes in promoter
occupancy [77, 80, 100]. Preliminary data from our laboratory suggest that these
interactions are determined in part by phosphorylation of specific residues within the
cytoplasmic tail of MUC1. How the mutational status of p53 influences these
interactions has not been explored. To study this, we designed a doxycycline-inducible
system to express specific p53 isoforms in pancreatic cancer cells. We found that the
hotspot mutant R273H appears to preferentially interact with MUC1, however, both
wildtype and R175H mutant p53 also interacted with MUC1. Furthermore, when we
examined expression of CTGF, a gene previously suggested to be regulated by the
interaction of p53 and MUC1 at upstream promoter elements [100], we found that
expression of R273H caused the most robust increase in expression of CTGF as
compared to wildtype or R175H p53. We also examined expression of MMP1, which is
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thought to be downregulated in response to this interaction [77]. We observed that both
wildtype and R175H caused a modest decrease in expression at low doses; however,
R273H was unable to decrease MMP1 expression. These results suggest that the
mutational status of p53 may influence particular gain-of-function effects on gene
targets. Furthermore, some of these effects may be dose dependent on the overall
levels of p53.
Interestingly, p53 expression did not alter the growth kinetics of Colo357 cells as
assessed by methylene blue assay. This suggests that under steady state conditions
these cells have become unresponsive to p53. However, when we irradiated cells we
found that wildtype p53 expression caused cells to cease growth sooner than either
R175H or R273H. When we examined the response of these cells to irradiation we
found that wildtype p53 was phosphorylated in response to DNA damage, whereas
neither mutant was phosphorylated under these conditions. Furthermore, wildtype p53
showed induction of the pro-apoptotic protein PUMA. These results suggest that
specific mutants of p53 may lose responsiveness to DNA damage stressors.

3. Results
Colo357 Cells Express High Levels of Endogenous MUC1 and no p53
To identify a suitable cell line for studies involving re-expression of different
isoforms of p53, we performed western blot analysis of several pancreatic cancer cell
lines. In order to minimize complications from variables in MUC1 and p53 expression
we sought a cell line that expressed endogenous MUC1 and either wildtype or no p53.
S2013 and Panc1 cells were not usable for these assays due to lack of endogenous
MUC1 expression and natural expression of mutant p53. We found that Colo357
expressed high levels of endogenous MUC1 (Figure 6.1). Furthermore, while Colo357
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are proposed to retain wildtype p53 alleles, we observed no p53 expression in these
cells making them the ideal cell line for our studies [318].

Designing a Dox-Inducible System for p53 Expression
As a starting point, we designed 3 distinct p53 constructs; wildtype, R175H, and
R273H (Figure 6.2A). The R175H and R273H mutations are both hotspot mutations in
the DNA binding domain and commonly occur in pancreatic cancer cell lines [319].
Furthermore, the R175H mutation is orthologous to the R172H mutation that was used in
generation of the KPC mouse model of pancreatic cancer. These mutations also
represent distinct classes of mutants, as R175H disrupts DNA binding by altering the
structure of p53, whereas the R273H mutation disrupts a residue involved in direct DNA
binding [311]. We cloned the human wildtype p53 cDNA sequence into the plvx.Tightpuro vector from Clontech (graciously provided by Dr. Angie Rizzino) and added a triple
flag sequence to the C-terminus to facilitate detection and isolation. Site-directed
mutagenesis was performed to generate mutants and sequencing was used to confirm
mutations (Figure 6.2B). To validate the induction of recombinant p53 in transduced
cells, increasing doses of doxycycline were applied in culture and p53 expression
assessed by western blot analysis by both a p53 antibody and an antibody against the
flag sequence (Figure 6.2C). Dose dependent induction of p53 was observed for all 3
constructs. Each cell line exhibited similar levels of p53 expression upon induction.

MUC1 Preferentially Interacts with the R273H Hotspot Mutant
To assess how the mutational status of p53 impacts interaction with MUC1, we
performed reciprocal co-immunoprecipitation assays for both proteins. Lysates were
prepared from each cell line and levels of p53 and MUC1 were similar in the sample
inputs for immunoprecipitation (Figure 6.3A). Immunoprecipitation of p53 was performed
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using M2 agarose beads and western blot analysis was performed for both p53 and coassociated MUC1. We observed a modest increase in associated MUC1 with the
R273H mutant; however, this result was confounded by the background signal from
antibody light chain used in the immunoprecipitation (Figure 6.3B). The reciprocal
experiment also showed increased association between MUC1 and R273H, supporting
the hypothesis that MUC1 shows enhanced interaction with this mutant as compared to
wild-type and R175H (Figure 6.3C), though there were interactions between MUC1 and
all 3 forms of p53.

Expression of R273H Causes Induction of CTGF Expression
Previous studies have shown that the interactions between MUC1 and p53
modulate the expression of MMP1 and CTGF by binding upstream promoter elements
[77, 100]. To examine whether the mutational status of p53 influenced the expression of
these genes, we treated Colo357.ip53 cells with no doxycycline, 300 ng/ml, or 1000
ng/ml to induce expression of wildtype, R175H, or 273H p53 respectively in each cell
line. RNA was isolated and expression of MMP1 and CTGF was evaluated by qRT-PCR
(Figure 6.4). Expression of p53 was also confirmed by two independent primer sets.
Induction of p53 was dose dependent and similar for each cell line as compared to their
untreated parental counterpart. MMP1 did not show substantial changes in expression,
though at 300 ng/ml both wildtype and R175H expression caused a modest reduction in
expression. This was abrogated at 1000 ng/ml suggesting potential dose dependent
effects. By comparison, CTGF expression was significantly induced by R273H
expression in a dose dependent manner. Wildtype and R175H p53 also showed modest
increases in CTGF, however, this was significantly less than R273H and only high dose
wildtype p53 reached statistical significance (p=0.048), suggesting R273H preferentially
induces CTGF expression.
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Mutant p53 is Less Responsive to DNA Damage
We performed methylene blue based proliferation assays to determine if different
p53 mutants influenced the growth of pancreatic tumor cells. Cells received either no
treatment or 1 µg/ml doxycycline refreshed daily for 1 week. Interestingly, under steady
state conditions we observed no significant impact of p53 expression on cellular growth.
This was true even for expression of wildtype p53 (Figure 6.5A-D). Under normal
cellular conditions, p53 often does not exert any effect on cellular growth until the cell is
stressed [208]. To test whether cells expressing p53 would respond differently in
response to stress conditions, we performed cell proliferation assays with 10 Gray
irradiation of the cells at 48 hours, and compared these results to our non-irradiated
controls. We found that irradiation decreased growth in all 3 cell lines as compared to
non-irradiated controls; however, both R175H and R273H cells maintained growth near
control levels until the 144 hour timepoint. In contrast, cells expressing wildtype p53
showed significantly decreased cellular growth at 120 hours (Figure 6.6A-C). These
results suggest that mutant p53 may be less responsive to induction of stress responses
in these cells.
To further investigate this hypothesis, we performed western blot analysis to
examine the induction of the stress response following DNA damage. Cells either
received no doxycycline or 1 µg/ml doxycycline with increasing doses of radiation. All 3
cell lines showed similar response profiles for phosphorylation of Chk1 and Chk2.
However, western blot analysis for phosphorylation of p53 at Serine 15, a residue
involved in stabilization and transcriptional activity, showed that only wildtype p53 was
phosphorylated at this residue (Figure 6.7). Cells that did not receive doxycycline
showed no induction of p53, confirming that the phosphorylated p53 we observed was
derived from the inducible recombinant construct. Additionally, at 20 Gray irradiation,
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wildtype p53 cells showed induction of the pro-apoptotic protein PUMA. This induction
was not observed in mutant p53 expressing cells. This difference appears to be specific
to irradiation, as UV damage was capable of inducing phosphorylation of all 3 p53 forms,
though R175H showed less phosphorylation than wildtype or R273H p53 (Figure 6.8).

4. Discussion
The interaction between MUC1 and p53 has been confirmed by a number of
independent studies [77, 80]. Interestingly, these studies show that MUC1 and p53 cooccupy promoters that are not regulated by p53 under normal circumstances. While
previous studies have shown that phosphorylation of the MUC1 cytoplasmic tail is an
important regulatory step of this interaction, no studies have evaluated the impact of p53
mutational status. As p53 is mutated in a significant fraction of pancreatic tumors,
mutation of p53 could significantly impact the outcome of these interactions [310]. We
evaluated how mutations impacted this interaction using wildtype, R175H, and R273H
mutants of p53. We found that the R273H mutant preferentially interacted with MUC1;
however, MUC1 showed interaction with all 3 p53 forms. Several studies have shown
that different p53 mutants can exhibit different gain-of-function effects within cancer
[235, 316]. The differential interactions suggest that MUC1 may play a role in the
regulation of these gain-of-function effects in pancreatic cancer. Indeed, previous
studies showing that MUC1 and p53 can alter the expression of CTGF and MMP1 were
performed using S2013 cells that carry the R273H mutation [77, 100]. Our studies
support a role for the R273H mutation in regulation of CTGF expression, as only our
inducible R273H cell line was capable of significantly inducing expression of CTGF.
Interestingly both wildtype and R175H p53 affected MMP1 expression with low dose
induction; however, this effect was abrogated with higher dose expression. This
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suggests that p53 mutants may also exhibit dose dependent effects on certain
promoters. As mutant p53 is significantly more stable than wildtype p53, some gain-offunction effects may be a result of changes of overall protein concentration in these dose
dependent experiments.
The fact that MUC1 is also capable of interacting with wildtype p53 suggests that
this interaction contributes to normal cellular responses. In normal tissues MUC1 is
spatially segregated from many receptor tyrosine kinases that can phosphorylate the
cytoplasmic tail [26]. Similarly, p53 expression is normally tightly regulated and
expressed at extremely low levels under unstressed conditions [208, 223]. However,
during mechanical injury, the barriers that normally separate MUC1 and RTKs can be
removed, allowing the two molecules to interact and engage in signaling. Cellular stress
also causes induction and stabilization of p53. As such, it is possible that the interaction
of MUC1 and p53 may represent a critical mediator of the response to cellular injury,
helping the cell to make a decision about whether to live or die. Cancer cells may co-opt
this mechanism and use it to survive stresses such as loss of polarity through
constitutive signaling through the MUC1 cytoplasmic tail.
Interestingly, under steady state conditions expression of p53 had no impact on
the growth of Colo357 cells. The fact that Colo357 also lacks detectable expression of
endogenous p53 suggests that these cells may have become largely insensitive to p53
expression. Irradiating cells resulted in cellular death and appropriate phosphorylation of
wildtype p53, suggesting that under stressed conditions p53 may still exert functional
effects in these cells. Furthermore, cells expressing wildtype p53 exhibited an earlier
decrease in proliferation in response to irradiation and induction of the pro-apoptotic
protein PUMA. These effects were diminished in both mutants suggesting that these
variants confer resistance to irradiation induced cell death by delaying or abrogating
induction of apoptotic proteins. Several studies have shown that mutants of p53 often
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fail to induce expression of the apoptotic protein Bax [242]. The interaction of MUC1
with p53 also preferentially blocks induction of Bax suggesting another means by which
this signaling axis delays or inhibits apoptosis [80].
Future studies examining gain-of-function effects of these mutants at promoter
elements will provide further insight into how MUC1 regulates the transcriptional
machinery of tumor cells. While we have observed differential interaction between
MUC1 and a few hotspot mutants of p53, design of additional mutants using the
hotspots at G245, R248, R249, and R282 could provide further insight into the molecular
mechanisms and effects of these interactions. Interestingly, preliminary data in our lab
suggest that MUC1 interacts with p53 through its regulatory domain, whereas the
hotspot mutations all reside within the DNA binding domain. This may explain why
MUC1 is capable of interacting with all 3 of our p53 species; however, mutation may
result in structural changes that alter the affinity of this interaction. In vitro biochemical
assays of interaction may allow us to better understand these dynamics and remains an
important area of future investigation.
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Figure 6.1: Expression of MUC1 and p53 in Pancreatic Cancer Cell Lines
Western blot analysis screening expression of MUC1 and p53 in the pancreatic cell lines
Panc1, S2013, and Colo357. Both Panc1 and S2013 cells lack endogenous MUC1
expression, requiring exogenous transfection to study MUC1. Furthermore, these cell
lines express the R273H mutant of p53 at detectable levels making them unsuitable for
our system. Colo357 cells represented the best combination of high endogenous MUC1
and no co-expression of mutant p53 and thus were chosen for our studies.
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Figure 6.2: Characterization of a Dox-Inducible p53 Expression System
We chose to study 2 hotspot mutants (R175H and R273H), as well as wildtype p53. A
general schematic (A) of the expressed protein is provided highlighting functional
domains, the site of mutation (star), and the attachment of a 3X Flag sequence for
detection. B) Generation of specific site mutations was confirmed by sequencing and a
chromatogram of the results is presented. The R175H and R273H mutant codons are
highlighted in red. C) Inducible expression of p53 was confirmed by western blot
analysis for both p53 (DO-1) and the Flag tag (M2). Increasing concentrations of
doxycycline resulted in a dose dependent induction of p53 in all 3 cell lines. β-actin was
used as a loading control. Consistent induction was confirmed by multiple replications of
the dose curve.
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Figure 6.3: MUC1 Preferentially Interacts with the R273H Mutant
Evaluation of the effects of mutation of p53 on interactions with MUC1: reciprocal coimmunoprecipitation assays. A) Western blot analysis of input samples confirming equal
concentrations of proteins were used for immunoprecipitation in all 3 cell lines. B)
Immunoprecipitation of p53 using M2 (anti-FLAG) agarose beads and western blot
analysis of p53 and MUC1 shows slightly increased levels of MUC1 pulldown in the
R273H lane; however, this interpretation is complicated by light chain reactivity detected
by the secondary antibody, as seen in the IgG control lane. C) Immunoprecipitation of
MUC1 shows increased co-immunoprecipitated R273H p53, as compared to wildtype
and R175H p53. IgG lanes confirm that the interaction is specific. Coimmunoprecipitation studies were repeated 3 independent times to ensure
reproducibility.
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Figure 6.4: R273H Preferentially Induces CTGF Expression
qRT-PCR analysis of p53, MMP1, and CTGF mRNA expression in Colo357.WTp53,
R175H, and R273H cell lines. Expression of each gene was normalized to the untreated
parental control. Induction of p53 was shown to be dose dependent and similar
induction is observed for all 3 cell lines. MMP1 expression showed modest decrease
with low dose expression of wildtype or R175H p53. This was abrogated with high dose
expression. All 3 p53 forms promoted some induction of CTGF, however only R273H
promoted a significant increase in CTGF expression in a dose dependent manner. At
high doses of Dox, expression of wildtype p53 induced CTGF above statistical threshold
(p=0.048). Statistics were performed using two-tailed student’s t-test comparing the
doxycycline treated lines to the untreated parental control. Each sample was performed
in triplicate in two independent experiments.
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Figure 6.5: Expression of p53 Does Not Impact Steady State Growth
Methylene blue assays measuring proliferation of all 3 p53 cell lines in the presence or
absence of 1 µg/ml doxycycline. Results are presented as the average absorbance at
650 nm. Expression of wildtype (A), R175H (B), or R273H (C) showed no significant
impact on growth as compared to the non-dox control cells. A comparison of all 3 lines
(D) shows that the form of p53 has no impact on steady state growth. Statistical
analysis was performed using 2-way ANOVA. Absorbance represents an average of 6
independent wells to control for variability in plating and growth due to plate position.
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Figure 6.6: Mutant p53 Delays the Onset of Radiation Induced Growth Inhibition
Methylene blue proliferation assays measuring cellular growth of p53 cell lines with or
without 10 Gray irradiation at 48 hours. Results are presented as the average
absorbance at 650 nm. With irradiation all cell lines showed slowed growth and showed
loss of proliferation at 144 hours. However, both R175H (B) and R273H (C) maintained
near control level growth until 144 hours, whereas wildtype p53 growth decreased 24
hours earlier (A). Statistical analysis was performed using 2-way ANOVA. Absorbance
represents an average of 6 independent wells to control for variability in plating, growth
due to plate position, and irradiation exposure.
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Figure 6.7: Mutation of p53 Alters Activation of DNA Damage Response
Colo357. WT p53 (A), R175H p53 (B), or R273H p53 (C) were treated with increasing
doses of radiation in the presence or absence of 1 µg/ml doxycycline. 1 hour postirradiation cells were lysed and examined by western blotting for induction of stress
related signals phosphoChk1, phosphoChk2, phosphoSer15-p53, as well as expression
of p21 and PUMA. All 3 lines showed similar profiles for phosphorylation of Chk1 and
Chk2. However, only wildtype p53 showed phosphorylation at Serine 15 and induction
of PUMA expression. Western blots are representative images of multiple experiments.
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Figure 6.8: R175H p53 Exhibits Altered Response to UV Damage
Colo357. WT, R175H, R273H, and control cells were exposed to UV irradiation to induce
DNA damage. 1 hour post UV exposure, cells were lysed and examined for
phosphorylation of p53 and p21 expression by western blotting. UV damage induced
phosphorylation of all 3 mutants, however, R175H showed diminished activity. Loss of
p21 expression indicates cells had initiated the apoptotic response. Western blots are
representative images of multiple experiments.
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Chapter VII: Summary and Future Directions
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7. Summary
The role of transmembrane mucins in the progression of cancer is well
established and the knowledge of their signaling capacity continues to grow [75, 81, 86,
87, 102, 268, 320, 321]. MUC1 remains the most studied of these mucins. The capacity
of MUC1 to alter the activity of different signaling cascades under different contexts has
been demonstrated; however, the manner and extent to which MUC1 integrates multiple
signals has not been well-characterized. We have demonstrated that the C-terminal
subunit of MUC1 exists in a wide array of modified states, including numerous distinct
phosphorylated forms, suggesting that MUC1 integrates several signals concurrently to
affect multiple signaling and biological pathways within the cell. Furthermore, changes
in biological conditions of the cell result in broad alterations in signaling and
transcriptional regulation, lending support to the hypothesis that MUC1 acts as a sensor
of the surrounding environmental conditions and commensurate modifier of cell activity
[19, 26]. Interestingly, specific MUC1 splice variants also appear to exist in extensively
modified states, suggesting additional means of regulating signaling pathways by
altering the N-terminal portion of MUC1 exposed to the extracellular space. Expression
of truncated glycans has also been shown to modulate the tumorigenic properties of
mucins, suggesting that while the C-terminus is engaged in signaling, the N-terminal
extracellular domain may play a significant role in the detection of the surroundings to
initiate or modify those signals [42, 73, 322, 323].
While several studies have shown the impact of MUC1 on downstream signaling
cascades such as ERK, few studies have evaluated the corresponding impact on
transcriptional activity downstream of these effectors [81, 86]. We found that expression
of MUC1 promoted shifts in the composition of the dimeric transcription factor AP-1 to
favor c-Jun:FRA-1 dimers, seemingly due to induction of upstream ERK activity. As the
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composition of AP-1 has been shown to influence the DNA binding properties of the
transcription factor, this suggests that MUC1 can reprogram gene expression by altering
the formation of specific transcriptional complexes [196-198]. As many transcription
factors are rapidly stabilized or degraded in response to post-translational modification,
the integration of extracellular signals through MUC1 may represent a critical regulatory
step of gene expression in response to changes in the environment. In our studies,
MUC1 expression resulted in increased expression of known targets of FRA-1 involved
in epithelial-to-mesenchymal transition. Preliminary studies also suggest that MUC1
expression increases occupancy of FRA-1 at these sites. Different stimuli may induce
differential downstream impact on transcriptional complexes, altering the gene
expression profiles accordingly. This may explain in part how MUC1 impacts numerous
pathways under different cellular contexts [87, 169, 274, 321, 324].
Interestingly, expression of FRA-1 itself also appears to play a role in pancreatic
tumor progression. Orthotopic tumor models demonstrated that knockdown of FRA-1
decreases tumor growth. These studies represent the first evidence for FRA-1 playing
an in vivo role in the progression of pancreatic cancer, which provides support for
previous in vitro evidence [289]. Gene and protein expression analysis of human PDAC
samples further suggests elevation of FRA-1 expression in PDAC. While we did not
observe significant correlations between FRA-1 and protein levels of EMT targets, future
studies utilizing more quantitative measures may allow for better models to study the
correlations between these proteins. Stratification of pancreatic cancer samples into
distinct subtypes may also provide clarity for these comparisons. Furthermore, in vitro
studies suggest that targeting FRA-1 may represent a viable option to decrease tumor
growth. While our studies did not demonstrate synergy between FRA-1 knockdown and
BETi, several other methods of targeting AP-1 dimers exist including DNA aptamers and
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specific AP-1 inhibitors and future studies may provide better insight into the targeting of
FRA-1 [309].
While the impact of MUC1 on the formation of AP-1 appears to involve upstream
signaling cascades, MUC1 has been shown to regulate the function of p53 through
direct binding [77, 80]. Interestingly, this results in changes to promoter occupancy of
complexes containing both p53 and MUC1. Mutation of p53 is extremely common in
pancreatic cancer and is often accompanied by gain-of-function effects, including
alterations to DNA binding capacity [235, 237, 314]. Our use of inducible models of p53
expression showed that MUC1 preferentially associates with the R273H p53 mutant as
opposed to wildtype or R175H p53. This p53 mutant appears to exert specific gain-offunction control at the CTGF locus, as expression of R273H in Colo357 cells can induce
expression of CTGF, whereas wildtype and R175H show relatively little induction.
Studies showing that MUC1 can regulate expression of CTGF have primarily been
performed using cell lines expressing the R273H p53 mutant, supporting the hypothesis
that MUC1 may preferentially exert gain of function effects with this mutant [100].
Interestingly, mutant p53 often binds DNA in a structure specific manner, suggesting that
mapping regions of predicted alternative DNA structures may provide insight into both
p53 and MUC1 binding in cancer. Studies correlating specific p53 to patient outcomes
may also help to identify p53 mutants that drive distinct gain-of-function effects within
pancreatic cancer.
While these studies have provided significant insight into biological roles of
MUC1 in gene regulation, induction of signaling cascades, regulation of transcriptional
complexes, and overall tumor progression, they remain limited through our lack of
quantitative understanding of the mechanism. Indeed, while MUC1 is known to drive
downstream signaling cascades, the rate at which this occurs and the magnitiude of the
effect is not known. This limits the predictive power of our model systems and hampers
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efforts to effectively target MUC1 and downstream effectors. Future studies using more
quantitative models, such as the CRISPR based systems, single cell imaging, super
resolution microscopy, and real-time tracking will allow us to better define the molecular
circuits involved in MUC1 signaling. The expansion of human samples available for
study through the UNMC Rapid Autopsy Program and Next Gen Sequencing datasets of
these samples will further allow for deep quantitative analyses allowing for better
understanding of the human condition and correlation of these models with in vitro
models. Expansion of studies from the biological systems into the computational
systems will allow for greater understanding of the complexities of pancreatic cancer and
offer many tools for the future study of pancreatic cancer.

7.1 Evaluate the Impact of MUC1 on the Global Promoter Occupancy
of p53, c-Jun, and FRA-1
We have shown that expression of MUC1 influences the formation of AP-1 to
favor c-Jun:FRA-1 dimers. Previous studies have shown that MUC1 displaces c-Jun
from both the MMP1 and CTGF promoters [77, 100]. No studies have evaluated how
MUC1 impacts the occupancy of these factors on a global scale. To address this
question, we have initiated experiments to isolate chromatin from MUC1 overexpressing
cells and their parental counterparts to perform ChIP-seq for c-Jun and FRA-1. Cooccupancy of c-Jun and FRA-1 at promoter elements will be confirmed using ChIPreChIP assays. Preliminary studies performing ChIP followed by qRT-PCR of select
sites showed changes in promoter occupancy of several FRA-1:EMT genes; however,
these preliminary studies need to be repeated and further optimized (Figure 7.1). These
studies will be paired with RNA-seq analysis of the cell lines to identify genes that are
differentially regulated due to changes in promoter occupancy. To date we have
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performed RNA-seq analysis of S2013.Neo and MIF cells, as well as FRA-1
overexpression and knockdown lines (Figure 7.2A). The differences in gene regulation
by FRA-1 between the S2013.Neo and MIF cells further support differences in global
DNA binding (Figure 7.2B).
The previous studies showing displacement of c-Jun from promoter elements
also highlighted increased occupancy of MUC1 and p53 at these sites [77, 100]. We
wish to examine how the mutational status of p53 influences its binding capacity at these
sites and others within the genome. Recent studies of p53 have shown that different
mutants of p53 retain different DNA binding properties [235, 236, 313, 314]. We have
shown that MUC1 preferentially interacts with the R273H hotspot mutant. Our qRT-PCR
data also suggests that different p53 mutants exhibit differential regulation of these gene
targets. We hypothesize that MUC1 may regulate certain gain-of-function effects by
regulating DNA binding depending on the mutant of p53 expressed. As such, we intend
to extend these studies to evaluate changes in p53 binding in conjunction with MUC1
expression using our dox inducible models of p53. Using ChIP-seq we can assess
whether different p53 mutants exhibit differential DNA binding with MUC1 expression.

7.2 Assess the role of MUC1 in the temporal regulation of AP-1
induction
Jun and Fos proteins are both immediate early genes and are rapidly induced in
response to various stimuli [121]. While we demonstrated that MUC1 could readily alter
the composition of the AP-1 dimer, we still don’t understand the stoichiometry and
temporal dynamics of this process. As different Jun and Fos proteins exhibit different
kinetics, the rise and fall of these proteins likely regulates the relative composition of AP1 over time. The expression of particular dimers may also be critical for the appropriate
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regulation of downstream gene targets over time. Furthermore, as MUC1 relays
information from the surrounding microenvironment, any changes in the surroundings
may result in a different temporal response if MUC1 is present or absent.
To study the levels of AP-1 proteins in real time, we are currently designing a
CRISPR based system that will allow for the generation of knock-in fluorescent Jun or
Fos proteins whose expression and interactions can be followed by fluorescence assays
and by Fluorescence Resonance Energy Transfer (FRET). This system is being
modeled on previous work by Dr. John Albeck, and he has generously provided initial
constructs that are being used as a framework for our studies [325]. These constructs
consist of homologous arms to c-Jun or FRA-1 as well as an in-frame cDNA sequence
for a fluorescent protein (Figure 7.3). These constructs are paired with a CRISPR
construct containing a specific sgRNA against genomic sequences within FRA-1 or cJun. After transfection, cells are sorted for fluorescence that should only be present in
cells that have undergone appropriate genomic editing. Initial pilot experiments have
shown modest efficacy (Figure 7.4). However, the number of positive cells has been
insufficient for experimentation to date. In order to increase efficiency of targeting, we
have moved to use lentiviral transduction of CRISPR constructs and mutation of specific
PAM sequences to eliminate non-specific cutting.
As a secondary approach, we are generating fusion protein constructs for AP-1
proteins should the CRISPR approach prove to be too difficult with the available
facilities. These constructs will allow us to study stabilization of AP-1 proteins in
response to post-translational modification, however, we will not be able to evaluate
responses that lead to increased AP-1 gene expression as these constructs won’t have
the endogenous genomic promoter elements and enhancers.
If our experimental system is successful, the response of AP-1 proteins will be
measured in real-time using live fluorescent microscopy of cells. How different stimuli
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influence responsiveness will be assessed by multi-well assays in which cells are treated
with various growth factors, drugs, or other stimuli in the presence or absence of MUC1
expression. Fluorescence intensity will be tracked over time and used as readout of AP1 protein levels and confirmed using time-course studies based on the real-time imaging
results.

7.3 Stratification of Rapid Autopsy Specimens by Molecular Subtype
In recent years, several studies have explored the diversity of pancreatic cancer
and categorized tumors on the basis of genomic, transcriptomic, and epigenomic
features [16-18]. Due to the robust stromal involvement in pancreatic cancer, these
studies remain controversial, as the molecular characteristics are often complicated
through the inclusion of non-tumor cells in the analysis. Within UNMC, we have access
to a substantial number (~100) of pancreatic tumor specimens through the UNMC Rapid
Autopsy Program (RAP). We will attempt to validate these subtypes through clustering
analysis of gene expression in these tumors. While previous studies have primarily used
RNA-seq to measure gene expression, this is a costly approach. In collaboration with
Dr. Fang Yu of the UNMC Biostatistics Department, we are incorporating transcriptome
data from the recent manuscripts to identify the most differentially regulated genes and
generate a smaller subset of genes to evaluate as biomarkers of biological subsets of
pancreatic cancer (Figure 7.5).
To test this gene set, we will perform hierarchical clustering based on Euclidean
distance using previously published work from other groups to assess how well this
signature can recapitulate the subtypes previously identified (Figure 7.6). As these
subtypes remain controversial, we will attempt to incorporate findings from multiple
studies to avoid overfitting the data or biasing our results to one paradigm or another.
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Once we have chosen a biomarker gene profile, we will perform digital PCR on RAP
samples using Nanostring technology to generate our expression profile. This
technology has the benefit of being more cost-effective than RNA-seq and requiring
lower RNA quality, which is easier to achieve with stored RAP specimens. We will then
perform unsupervised clustering of our gene expression and identify the number of
subtypes observed and compare them to previously published subtypes. These
stratified groups can then be used for further analyses examining survival, treatment
response, metastatic spread, and correlation with protein expression.

7.4 Evaluate the Biochemical Properties of the MUC1:p53 Interaction
and Expand Gain-of-Function Studies of Mutant p53.
The interaction of MUC1 and p53 is postulated to involve the regulatory domain
of p53, however, this does not explain why we observe differences in the interaction with
mutations occurring within the DNA binding domain of p53 [80]. In order to effectively
function as a transcription factor, p53 must oligomerize to form a tetramer. Previous
studies in the lab have suggested that MUC1 may modulate the ability to form these
oligomeric complexes, however, these studies remain unconfirmed. In collaboration
with Edwin Wiest, we have focused on purifying recombinant MUC1 and p53 (Figure
7.7). The interactions between these two proteins will then be assessed by biochemical
assays including Isothermal Titration Calorimetry (ITC). We will further explore the
impact of mutation through the generation of specific p53 mutants, including the R175H
and R273H mutants previously studied.
We would also like to further expand our studies to include additional hotspot
mutants at G245, R248, R249, and R282. These mutants will be generated in our Dox
inducible system and validated using the same approaches used for R175H and R273H.
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As p53 can also utilize internal start sites and splice sites, we would like to additionally
generate inducible constructs of these variants. We have already generated the Δ40p53
variant (Figure 7.8). As these proteins exhibit different transcriptional and regulatory
dynamics, they may further influence the gain-of-function effects observed within cancer.
There has also been no exploration of whether these variants are capable of interacting
with MUC1. To evaluate the putative roles mediated by association of MUC1 and p53,
and those driven by p53 alone, we intend to expand these studies to include shRNAmediated knockdown or CRISPR knockout of MUC1.

7.5 Evaluation of FRA-1 Expression and its Role in Early Pancreatic
Cancer Development
In cancer, deregulation of immediate early gene products, such as c-Myc, is
extremely common [326]. Expression of these genes is often rapidly induced in
response to oncogene expression, typically as a result of post-translational stabilization
due to constitutive signaling. As a result, many of these genes play a critical role in the
development and progression of early tumors. In pancreatic cancer, mutation of Kras is
the most common driver of tumor development [13]. Several studies have shown that
the pro-oncogenic activity of AP-1 proteins, like c-Jun and FRA-1 relies on co-expression
of an oncogenic driver like Kras [287, 301, 327]. We found that expression of FRA-1
promoted increased invasive behavior and knockdown of FRA-1 decreases tumor
growth. Furthermore, while we found that tumors typically exhibited increased
expression of FRA-1, the stage at which this occurs remains unknown.
To evaluate expression of FRA-1 in early tumor development, we will perform
immunohistochemistry for FRA-1 using PanIN confirmed slides. In preliminary studies,
we found that FRA-1 expression does not substantially increase until PanIN-3 (Figure
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7.9). This is despite the presence of Ras mutations in earlier PanIN lesions, suggesting
that additional regulatory changes must occur before FRA-1 is stabilized. Interestingly,
expression of miR-34 is lost in later stages of development (PanIN-3 to PDAC) [328].
Expression of miR-34 has been shown to inhibit expression of FRA-1 and is normally
regulated by p53, suggesting that loss of p53 and miR-34 may be critical events for
induction of FRA-1 [329, 330]. Further immunohistochemistry with expanded samples
will help to confirm the stage at which FRA-1 expression increases. Pairing these
studies with expression of p53 and miR-34 will further elucidate the genomic alterations
critical for FRA-1 induction.
In long-term studies, it would be of interest to cross FOSL1 floxed mice into the
KC and KPC mouse models of pancreatic cancer. These studies would tease out the
importance of FRA-1 expression in the formation and progression of pancreatic cancer.
Furthermore, comparing the results from KC and KPC mice may allow for the
determination of the importance of p53 in these effects. Unfortunately, the FOSL1 floxed
mouse is not publicly available at this time.
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Figure 7.1: MUC1 Expression Alters Occupancy of FRA-1 at EMT Gene Promoters
FRA-1 bound chromatin was immunoprecipitated from S2013.Neo and MIF cells and
analyzed for promoter occupancy by qRT-PCR. Known sites of promoter binding were
used for AXL, FN1, SNAI2, and TGFB2, and normalized to IgG and Input controls.
MUC1 expression resulted in increased occupancy at genes involved in EMT (AXL, FN1,
SNAI2), however, TGFB2 showed no substantial enrichment.
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Figure 7.2: Differential Expression of Select Genes in S2013.Neo and MIF Lines
A) Table of differentially regulated genes between S2013.Neo and MIF cells. Genes on
the left are upregulated (green arrow) in MIF cells. Genes on right (red arrow) are down
regulated in MIF cells. B) Venn diagrams highlighting the differential regulation of FRA-1
targets in S2013.Neo and MIF cells. MIF cells show higher numbers of unique targets
as compared to Neo cells suggesting changes to FRA-1 function between the lines.
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Figure 7.3: Vector Maps of Homologous Constructs for AP-1 CRISPR
Vector map showing the design of homologous arm constructs for the generation of
FRA-1 and c-Jun fluorescent protein fusions using CRISPR. Homologous arms are
approximately 1.5kb sequences up or downstream of CRISPR cut site. Fluorescent
protein sequence lacks ATG start site requiring genomic incorporation to yield a
functional product.

Figure 7.3
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Figure 7.4: Validation of CRISPR Constructs
CRISPR constructs targeting either FRA-1 or c-Jun were transfected into S2013 or 293A
cells with homologous donor constructs. Cells were assessed for expression of
fluorescent fusion products by confocal microscopy. A small number of red (FRA1) and
yellow (c-Jun) cells are observed in each study confirming that the CRISPR constructs
are functioning.
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Figure 7.5: Differential Expression of Genes Between PDAC Subtypes
Using previously published expression data from the PDAC subtype manuscript by
Bailey, et al [18], and box plots for each of the approximately 18,000 genes examined
were generated using R-programming language. Statistical analysis of differential gene
expression was performed using both SAM and LIMMA methods. Genes that were
differentially regulated between specific subtypes are presented as validation of these
analyses.
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Figure 7.6: Hierarchical Clustering of Tumors by Gene Expression Profile
Gene expression profiles were identified from Bailey, et. al [18] manuscript of pancreatic
cancer subtypes. These profiles were than used to perform hierarchical clustering
based upon Euclidean distance to determine how many genes were required to
recapitulate the original findings.
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Figure 7.7: Purification of Recombinant MUC1
E. Coli optimized cDNA sequence for MUC1 was cloned into the pGEX.4T1 expression
vector to generate recombinant GST-tagged MUC1. These constructs were transfected
into C41 or C43 bacterial cells and recombinant MUC1 isolated using a GST column.
Purification was confirmed by western blot analysis of elution fractions (E1-E6).
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Figure 7.8: Expression of Dox-Inducible p53 Truncated Mutants
A) Schematic of additional p53 constructs designed. Tagless p53 lacks the 3X Flag
sequence. FL-p53 should only express full-length p53, whereas Δ40p53 should express
N-terminally truncated p53 lacking the first 40 amino acids. B) Mutations of methionine
to valine were introduced into the p53 sequence to generate FL p53 and Δ40p53. DO-1
epitope is highlighted to show that Δ40p53 is not detectable with this antibody. C)
Inducible expression of these constructs was measured with 1 µg/ml doxycycline and
western blot analysis for both p53 (DO-1) and the Flag tag. Overlay of these two signals
highlights FL-p53 in yellow, whereas tagless is absent by Flag and Δ40p53 is absent by
DO-1. Interestingly, FL p53 induces a predicted full-length size as well as another
truncated form smaller than Δ40p53, suggesting utilization of another internal start site at
amino acid 133 or 160. These studies suggest that for full design of the system, these
methionine residues will all have to be mutated.
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Figure 7.9: Expression of FRA-1 in PanIN Lesions
Immunohistochemistry was performed on PanIN lesion slides to assess expression of
FRA-1. 3 separate slides were used for each lesion (PanIN-1 through 3).
Representative images for each stage are shown (PanIN-1 through PDAC). Heatmaps
showing the relative expression are presented showing that FRA-1 is only modestly
expressed until the PanIN-3-PDAC transition.
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